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SUMMARY 
This thesis focuses on two separate topics, one lying at the intersection of health 
care and statistics, and the other one rising from classical statistical inference. Chapters 2 
through 4 address the first topic. They explore and improve techniques for comparing both 
efficacy and cost-effectiveness of cancer therapies. Chapter 5 focuses on the second topic. 
It proposes a new estimator for the number of binomial experiments when the success 
probability is unknown. 
Chapter 2 of my thesis establishes an overall ranking of efficacy of possible 
interventions in patients with advanced or metastatic melanoma within a Bayesian setting.  
Currently, chemotherapy is established as the standard of care for melanoma, but is often 
associated with poor responses and short survival. However, recent groundbreaking 
discoveries in tumor biology and immune surveillance have yielded effective molecularly 
targeted therapies and immune agents. These new treatments have changed the therapeutic 
scenario to a completely new reality of high response rates, prolonged disease control, and 
the possibility of talking of a cure for some patients. These positive results have opened 
new avenues in the treatment of melanoma patients and, as expected, added layers of 
complexity to management of those patients. We perform a network meta-analysis in a 
hierarchical Bayesian random-effects model to assess the role of immunotherapies and 
targeted therapies. We also evaluate the impact of immunotherapy biomarkers within a 
hierarchical Bayesian setting with a view to support and improve the therapeutic decision-
making process. 
 xvi 
Chapter 3 evaluates indirectly the effectiveness of two treatments for advanced 
castration-resistant prostate cancer (CRPC). Prostate cancer is the most commonly 
diagnosed cancer. It eventually progresses to CRPC. CRPC is one of the leading cause of 
cancer-related deaths among men in developed countries. Two novel androgen receptor 
pathway inhibitors, abiraterone acetate and enzalutamide, have recently become available. 
They have been developed with the aim of prolonging survival, minimizing complications, 
and maintaining or improving quality of life in patients with advanced or metastatic CRPC. 
However, these two treatment options have not been compared head to head against each 
other in a prospective randomized fashion. In order to choose the optimal treatment and 
the optimal sequencing of treatments, we perform two analyses. The first one is a 
comparative effectiveness study within a Bayesian hierarchical setting. The second one is 
a sequencing assessment of treatments in the context of exponential survival models, 
informed by Bayesian meta-analyses with between and within study variance components.  
Chapter 4 proposes an improved methodology for conducting both meta-analysis 
and secondary data analyses based on randomized controlled trials. One of the deficiencies 
inherent to traditional methodology is the lack of individual patient-level data which serves 
as a basic ingredient for secondary analyses. This shortcoming is handled by recovering 
the raw time-to-event data through the inverted Kaplan-Meier equations and simulations. 
The recovered survival distributions are then modeled within a Bayesian semi-parametric 
framework. We use a hierarchical Dirichlet Process to model discrete-time event 
probabilities across the time-line up to last follow-up, and a truncated Weibull model to 
model the tail of the distribution. This approach avoids assumption about the shape of the 
survival distributions up to the last follow-up time, allows incorporation of censored data, 
 xvii 
and accommodates study-to-study heterogeneity. The parametric nature of the Weibull 
model on the other hand is well suited to making inferences about the survival curve in the 
absence of data. Finally, patient-level disease trajectories are modeled using a Bayesian 
Markov model. We demonstrate this methodology using simulations and a study on 
advanced non-small cell lung cancer.  
Finally, Chapter 5 presents a new approach to the binomial n problem, which 
concerns the estimation of the number of binomial experiments when the success 
probability is unknown. Some real-life situations, where the problem arises, include the 
estimation of the number of unreported crimes as well as the number of undetected 
software errors. Due to its inherent instability, the problem remains fundamentally difficult. 
Furthermore, neither one of the two parameters of the binomial distribution are unbiasedly 
estimable when both are unknown. We present an efficient method of estimating the 
number of trials using a beta-binomial MLE approach. In the absence of replications, when 
inference about the parameter of interest is not possible, we present a Bayesian approach 
applied in the context of contingency tables.
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CHAPTER 1. INTRODUCTION 
In recent years, many new scientific and technological advancements have emerged, 
and an overwhelming amount of data has become available. On the scientific and 
technological front, there has been an exponential progress and advancement in many 
fields. Some discoveries in the past 15 years include reprogramming of stem cells [1], 
confirming the existence of dark matter [2], producing self-driving cars [3], and others. On 
the data front, facilitated by the internet of things, the role of data has rapidly evolved. The 
astonishing volume and variety of data, that has recently been produced, has transformed 
the world into so called data-driven reality.  
Science, technology and data go hand in hand. Data is a key ingredient to developing 
new scientific and technological tools. Science and technology are necessary to produce, 
collect, process and understand data. The high-impact nature of the three fields together 
has provided many opportunities. Together, they are integral components of the decision 
making and policy making process. However, sometimes limitations on the scientific and 
technological front lead to knowledge gaps on the data front. Scientific and technological 
research is often restricted by funding, time, resources, or all three together. These 
limitations present a challenge because knowledge gaps can in turn hinder the decision-
making process and prevent further scientific and technological progress. This thesis 




1.1 Part I 
The first part of this thesis focuses on bridging certain knowledge gaps related to cancer 
care. The goal of Chapters 2 through 4 is to support and improve the therapeutic decision-
making process and direct future scientific and technological cancer research efforts.  
In recent years, there has been a wave of dramatic successes in the research and 
treatment of cancer. This progress has been the direct result of revolutionary scientific and 
technological advances as well as new development in data analysis. A few such novel 
therapeutic/ diagnostic development approaches include immunotherapy, tumor-agnostic 
therapy, adoptive T cell therapy, as well as gene therapy. The pace at which the US Food 
and Drug Administration (FDA) is approving new cancer treatments is unprecedented. In 
2016 alone, the FDA approved five uses for immune checkpoint inhibitors in cancer care 
[4]. From November 2016 through October 2017, the FDA approved a record eighteen new 
cancer treatments and thirteen uses of cancer therapies [5]. With an increased availability 
of treatments, physicians face an increasing number of treatment options. However, 
usually, only a small fraction of the treatments are directly compared against one another 
in a prospective randomized fashion. Trials are expensive. Funding for clinical research, 
on the other hand, is limited. Additionally, clinical trials take years to conduct, and cost 
oncologists’ work and patients’ lives. Often, conducting studies is not feasible. This is 
problematic when deciding between compelling treatments that haven’t been directly 
compared before or when choosing the best treatment for a particular patient when an 
overall ranking of all possible treatments is lacking.  
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The primary goal of Chapter 2 is to establish an overall ranking of efficacy of possible 
interventions in patients with advanced or metastatic melanoma. Malignant melanoma is 
one of the most aggressive types of cancer [6]. Before recent therapeutic advances, once 
the disease progressed to a metastatic stage, it was almost always fatal [7, 8]. Recent 
groundbreaking discoveries in tumor biology and immune surveillance have yielded 
effective molecularly targeted therapies and immune agents in patients who have reached 
metastasis. Immunotherapies are treatments that boost the immune system. 
Immunotherapy was named Advance of the Year in ASCO’s 2017 cancer progress report 
[4]. Molecularly targeted therapies target specific disease genes or proteins associated with 
them. Immunotherapies and targeted therapies have rapidly changed the outlook for cancer 
patients. They have achieved high response rates, prolonged disease control and improved 
survival [9-13]. Both strategies have changed the therapeutic scenario of advanced 
melanoma, turning the clinical decision-making a challenging task. With these major 
advances in research and multiple options now available, a better understanding of how all 
available treatments compare to each other is needed for selecting the right treatment for a 
particular patient. However, only a handful of those treatments have been compared 
directly against each other in a clinical study setting. To fill this knowledge gap, this 
chapter presents extended comparisons of immunotherapies and targeted therapies for 
advanced melanoma by incorporating direct and indirect evidence from sixteen published 
trials. Additionally, we evaluate the impact of certain expressions and mutational status on 
immunotherapy efficacy.   
Chapter 3 performs a comparative effectiveness analyses between two compelling 
treatments in advanced castration-resistant prostate cancer (CRPC) that haven’t been 
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directly compared before. Prostate cancer poses a significant health problem today. It is the 
second most common cancer among men [14].  In 2017, prostate cancer alone accounted 
for almost one in five new cancer diagnoses [15]. Most prostate cancer patients with 
metastases eventually progress to CRPC within a median of one year [14]. As a result of 
research efforts over the past decade, two novel treatments, abiraterone acetate and 
enzalutamide, have recently emerged for the treatment of CRPC. Both therapies are 
androgen receptor pathway inhibitors. Androgen receptor has been shown to play an 
important role in the development and progression of prostate cancer [16]. Abiraterone and 
enzalutamide have each been shown to prolong survival [17, 18]. However, these two 
treatments haven’t been directly compared before in a randomized study. To bridge the gap 
between practitioners and patients, we compare indirectly the effectiveness using evidence 
from four randomized trials. We also investigate the optimal sequence of treatments.  
Finally, Chapter 4 assesses the cost-effectiveness of pembrolizumab as compared to 
chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Lung cancer 
is one of the most common causes of cancer related death [15]. It is the single leading cause 
of cancer death among those aged 40 years or older [15]. Due to relatively late diagnosis 
of lung cancer cases, scientific advances for lung cancer have been slower in contrast to 
most other cancers [15]. As of 2013, platinum-based chemotherapy was standard treatment 
for most patients with NSCLC [19]. However, recent scientific advances have led to the 
discovery of new paradigms for the treatment of NSCLC. In particular, immunotherapies 
have shown promising results. One such novel treatment is pembrolizumab. In late 2016, 
preliminary results of a new randomized trial showed superiority of pembrolizumab over 
standard platinum-based combination chemotherapy [20]. The FDA granted 
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pembrolizumab accelerated approval for the treatment of patients with metastatic NSCLC 
[21]. Pembrolizumab has shown impressive clinical results, but analysis of cost-
effectiveness of new therapies is imperative to ensure that they are used in an appropriate 
and sustainable manner. Currently, such cost-effectiveness analysis is lacking. We assess 
the cost-effectiveness of pembrolizumab in both the United States, and the United 
Kingdom.  
Throughout chapters 3 and 4, we address one additional issue, that is the lack of raw 
time-to-event data at the individual level. Currently, the standard practice in reporting of 
results from randomized controlled trials is to publish summary statistics, and not the raw 
data. Alsheikh-Ali et al found that only 9% of original research papers published in high-
impact journals made the raw research data available [22]. The summary statistics that are 
usually reported include efficacy measures such as hazard ratios and odds ratios. And yet, 
these measures do not constitute sufficient statistics for conducting secondary analysis, 
such as treatment efficacy analysis, cost-effectiveness analysis, analysis of sequencing of 
treatments, and others. We overcome this shortcoming by reconstructing the patient-level 
survival data.  
In conclusion, part I of this thesis aims to provide and improve evidence-based 
knowledge with a view to help practitioners with the development of new policies and 
practices related to cancer care.  
1.2 Part II 
The second part of this thesis bridges the knowledge gap in certain scenarios where 
data cannot be observed due to limitations, and has to be inferred instead. Consider the 
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following three scenarios. The first one is presented by Draper and Guttman and involves 
an appliance repair company [23]. The company is interested in estimating the number of 
a certain type of appliance in use in a certain service area based on the weekly total number 
of defective appliances sent in for repair. The second scenario is concerned with the 
estimation of the total number of crimes when many of them remain unreported [24]. 
Finally, the third one is related to software systems [25]. Often, there are errors introduced 
in the software development process. Reviewers can inspect for errors, but often a few 
errors remain undetected, and the estimation of the number of undetected errors becomes 
an important task. In these three scenarios, we observe partial counts (number of defective 
appliances, number of reported crimes, and number of detected errors), while the real 
interest lies in the total unobserved counts (total number of appliances, total number of 
crimes, and total number of errors respectively). And yet, the probabilities of observing a 
certain number of defective appliances, or crimes, or errors are also unknown. In Chapter 
5 of this thesis, we focus on bridging the gap between what is observed and what cannot 
be observed, and estimate the number of binomial experiments when the success 
probability is unknown.  
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CHAPTER 2. A SYSTEMATIC REVIEW AND NETWORK 
META-ANALYSIS OF IMMUNOTHERAPY AND TARGETED 
THERAPY FOR ADVANCED MELANOMA 
2.1 Introduction 
Recent groundbreaking discoveries in tumor biology and immune surveillance have 
yielded effective molecularly targeted therapies and immune agents, changing the scenario 
from one of poor responses and short survival to a completely new reality of high response 
rates, prolonged disease control, and the possibility of talking of a cure for some patients 
[9-13]. Blocking the BRAF-MEK pathway–commonly hyperactive in melanoma–has 
proved worthwhile. A sizeable number of trials have shown that BRAF inhibitors (BRAFi) 
and MEK inhibitors (MEKi) improve clinical outcomes when compared to chemotherapy 
[26-32]. The role of the immune system in controlling melanoma is well established and 
immune checkpoint inhibitors have shown promise in reinvigorating the immune system, 
successfully showcasing the enormous potential of drugs that manipulate immune 
surveillance for the first time in oncology [33-37].  
These positive results have opened new avenues in the treatment of melanoma 
patients and, as expected, added layers of complexity to management of patients with 
advanced disease. A number of studies have compared competing treatments to one 
another, but an overall ranking of possible interventions is lacking. The number of options 
has grown markedly and defining the best therapeutic plan for a particular patient is now a 
formidable task. This Bayesian network meta-analysis of randomized controlled trials aims 
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to establish relative efficacy of immunotherapy, molecularly targeted therapies, and 
chemotherapy, either alone or in combination, in patients with advanced or metastatic 
melanoma with a view to support and improve the therapeutic decision-making process. 
2.2 Patients and Methods 
2.2.1 Search strategy 
We searched PubMed, Embase, Clinicaltrials.gov, Cochrane Central Register of 
Controlled Trials, World Health Organization International Trial Registry, drugs at FDA, 
and Society of Melanoma Research, ASCO, ESMO, and ECCO meetings using a 
combination of broad terms related to melanoma and drug therapy, namely melan*, 
random*, immunotherapy, BRAF*, MEK*, and chemotherapy (full list of terms in 
Appendix A). References in recovered studies and relevant reviews were also screened. 
Databases were searched from their inception until December 21st 2015. No language 
restrictions were applied. We followed a predefined protocol (PROSPERO number 
CRD42016038618) in accordance with the PRISMA guideline for network meta-analysis 
[38]. 
2.2.2 Study selection 
We searched databases and assessed eligibility of studies based on abstracts and  
full texts, resolving disagreements by consensus. Eligible studies were (1) randomized 
controlled trials enrolling patients with metastatic or advanced melanoma and describing 
outcomes of interest, (2) randomized patients to chemotherapy, targeted therapy against 
the BRAF/MEK axis or immunotherapy (not vaccine, viral therapy or biochemotherapy), 
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and (3) BRAF and/or MEK inhibitor trial restricted inclusion to patients known to harbor 
BRAF mutations. Second-line BRAF-MEK inhibitor studies were eligible if the first-line 
therapy had not been BRAF-targeted therapy. Studies with insufficient follow-up (≤6 
months) or comparing different chemotherapy regimens were excluded. In the case of 
duplicated publication on the same study, the most up-to- date data were used. We 
acknowledged that inclusion criterion (4) would exclude NRAS-mutated patients. 
2.2.3 Data extraction 
We retrieved data from randomized control trial (RCT) full publications and relevant 
appendices guided by an extraction form. The items of interest were: trial name, first 
author, year of publication, number of patients, length of follow-up, methodology details 
(randomization, allocation concealment and blinding methods, use of intention to treat 
analysis), intervention details (drugs, doses, length of use), patient characteristics (median 
age, performance status, previous therapy, if any) and outcomes of interest (overall 
survival, progression-free survival, response rate). Disagreements were resolved by 
consensus. 
2.2.4 Outcomes of interest 
Hazard ratios for overall survival (OS) and progression-free survival (PFS), and odds 
ratios for response rate (RR), were collected or calculated for all included RCTs. We 
abstracted data from original intention-to-treat multivariate analysis whenever possible; 
thus, avoiding those derived from landmark analysis or solely based on median 
comparisons. We adhered to the definition of progression and the criteria used by each trial 
[39]. 
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2.2.5 Data synthesis and statistical analysis 
The comparison of treatments was performed by incorporating both direct and 
indirect effects within a Bayesian network meta-analysis. Standard meta-analysis is a 
method of combining evidence from multiple trials of a single comparison into a single 
effect size. The key here is that traditional meta-analysis does not allow the comparison of 
treatments if they have not been previously compared directly in a RCT.  
The idea behind network meta-analysis was only recently proposed and generalized 
by Bucher (1997) and Hasselblad (1998) [40, 41]. The term network meta-analysis was 
later coined in 2002 by Lumley, who proposed the application of linear mixed model in the 
presence of multiple treatments [42]. The network meta-analysis model allows the 
assessment of relative effectiveness of two treatments when they have not been compared 
directly in a RCT but have each been compared to other treatments. It strengthens inference 
regarding relative efficacy of treatments by synthesizing both direct and indirect evidence 
into a single effect size. Additionally, it facilitates the simultaneous ranking of all 
treatments and provides a global estimate of comparative treatment effectiveness. Most 
importantly, it allows the estimation of within- and between-study heterogeneity and the 
detection of inconsistency between randomized trials.  
The method proposed by Lumley is restricted to trials with only two arms. To 
overcome this limitation, Lu and Ades extended the meta-analysis model developed by 
Smith, Spiegelhalter and Thomas [43], and proposed a hierarchical Bayesian network 
meta-analysis for multi-arm studies based on Markov Chain Monte Carlo algorithm [44]. 
 11 
We performed network meta-analysis within a hierarchical Bayesian random-effects 
model, with relative efficacy measures, hazard and odds ratios, analyzed on the log-scale 
and random effects for study: 
log 𝜃𝑖,𝑗 ~Normal(𝑥𝑖,𝑗
′ 𝛽, 𝜎𝑖
2 + 𝜏2) 
where  
𝜃𝑖,𝑗 ∶   hazard ratio (odds ratio) 𝑗 reported in study 𝑖  
𝑥𝑖,𝑗 ∶  treatment contrast 𝑗 in study 𝑖 
𝛽 ∶  vector of treatment effects relative to chemotherapy 
𝜎𝑖
2 ∶  within − study variance for study 𝑖 
𝜏2 ∶  between − study variance in treatment comparisons.  
The distribution of all parameters was weighted by a distribution of prior beliefs. 
Parameters were given either non- or weakly informative priors letting the pooled data 
dominate the posterior distribution. Weakly informative priors were used for the mean 
treatment effects, placing 95% of the prior probability on hazard (odds) ratios between 1/10 
(1/20) and 10 (20), so that the pooled data dominated the posterior distribution. In 
particular, the effectiveness of treatment 𝑘 relative to chemotherapy 𝛽𝑘 was given the 


















) for odds ratios
. 
 Priors for individual within study variances 𝜎𝑖
2 were specified via inverse gamma 
distribution with reported value as its mean and variance proportional to 𝐷𝑖, the number of 
events for OS or PFS outcomes 
𝜎𝑖









2 is the reported variance for study i. For studies that did not report number of 
events (death for OS and progression or death for PFS), number of events were estimated 
by proxies as follows: for OS the assumption was that 50% of the randomized patients died, 
and for PFS 75% had PFS events by study cut-off.  


















) for odds ratios
, 
which allows hazard (odds) ratios to vary by up to two-fold (five-fold) across studies.  
 Finally, within-study correlation among the two relative efficacy measures in the 
three arm trials was modeled as bivariate normal whose marginal distributions matching 
those described above and having a correlation coefficient, 𝜌. A non-informative prior 
distribution  
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𝜌 ~ 𝑈(0,0.95) 
was taken for 𝜌. 
Estimates from three-arm studies were modeled in the context of a bivariate normal 
distribution with the same weakly informative prior on the between study variance along 
with an uninformative prior on the within-study correlation.  
Samples from the posterior distribution of the parameters were generated via Markov 
Chain Monte Carlo implemented through JAGS within R http://mcmc-
jags.sourceforge.net/[45-47]. Ten chains were used with the first 100,000 iterations of each 
discarded as “burn-in”. Results are based on 500,000 iterations from each chain, thinned at 
a lag of 100.  
We calculated posterior mean hazard and odds ratios for relative efficacy of each 
therapy, along with credible 95% intervals, predictive 95% intervals, and probabilities of 
each treatment being better than a reference were calculated. Therapies which achieved the 
combined benchmarks (a) overall survival (OS) posterior mean HR ≤ 0.8 with probability 
better ≥ 80% as compared to chemotherapy, (b) progression-free survival (PFS) posterior 
mean HR ≤ 0.6 with probability better than chemotherapy ≥ 90%, and (c) response rate 
(RR) posterior mean OR ≥ 3.0 with probability better than chemotherapy ≥ 95% were 
deemed to have a meaningful benefit as compared to chemotherapy [48]. 
Additionally, we performed a traditional pairwise meta-analysis for all treatments 
that have been directly compared in a trial before. We used a model similar to the approach 
of DerSimonian and Laird published in 1986 [49]. 
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We tested the hypothesis that BRAF mutation status alters relative efficacy of 
immunotherapy. Interactions between BRAF mutation status and relative efficacies were 
incorporated in the model. We also tested the hypothesis that PD-L1 expression affects 
relative efficacy of immunotherapies CTLA-4-PD-1 dual blockage, PD-1 blockage and 
CTLA-4 blockage. We adhered to the trial definition of PD-L1 positivity. 
Study-to-study heterogeneity was summarized using predictive intervals, which 
provide an interval in which the relevant comparative efficacy measure would be expected 
to fall for a new study. Ranking and probabilities were calculated based on predicted 
relative effects drawn from the posterior. Quality of studies was assessed via Cochrane 
Collaboration’s tool for assessing risk of bias in randomized trials [50]. Publication bias 
was graphically assessed via funnel plot. 
2.3 Results 
2.3.1 Systematic review 
A total of 1750 published or presented titles and abstracts were screened. After 
duplicated review and discussion, 18 trials on 10 types of therapy, comprising 7596 
patients, had their data extracted. All trials were multicentric and reported in English. A 
sizeable number of trials used chemotherapy (dacarbazine, paclitaxel or temozolomide) as 
control arm. Trials assessing BRAF-MEK dual blockade used BRAFi as control arm and 
restricted enrollment to patients harboring BRAF mutations. When dealing with trials 
comparing MEK-chemotherapy versus chemotherapy, we restricted the data to BRAF-
mutated patients. No trial performed a head-to-head comparison of immunotherapy versus 
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BRAFi. The majority of excluded randomized trials failed to use BRAFi or immunotherapy 
as active comparator. 
Two trials have been omitted from the main analysis as they have not produced 
relevant data; one comparing dacarbazine to dacarbazine and ipilimumab and other 
comparing ipilimumab to ipilimumab and sargramostim (available upon request)[36, 51]. 
Hence, the main analysis gathered data from 16 trials with eight therapeutic nodes and 
6849 patients [26-28, 30, 33-35, 52-66]. 
All included evidence was intention-to-treat, based on standard analyses, from 
studies with low risk of bias, according to the Cochrane risk of bias tool (provided in Figure 
23 in Appendix A). No sign of publication bias was found using the funnel plot (provided 
in Figure 24 in Appendix A). The schematic flowchart of systematic review is presented in 
Figure 1. Table 1 summarizes the trails included in the main analyses. 
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1750 records after 
duplicates removed 
1587 records excluded: 
 1477 not randomized 
 (retrospective, narrative reviews) 
 57 randomized to chemotherapy only 
 19 subgroup analyses 
 34 not advanced disease 
145 full-text articles excluded: 
 35 randomized to chemotherapy only 
 34 not randomized 
 32 trials in progress 
 25 biomarker analysis 
 7 updates on quality-of-life 
 3 not testing a standard BRAFi   
 [sorafenib] 
 2 testing endothelin inhibitor 
 2 testing elesclomol 
 2 different doses of same   
 immunotherapy 
 2 MEK therapy for BRAF status   
 unknown 
 1 MEK therapy for NRAS mutant only 
 1 different chemotherapies combined to      
 same immunotherapy 
163 full-text articles 
assessed for eligibility 
18 studies included in 
quantitative synthesis 
(16 in the main meta-
analysis) 
1750 records screened 
18 studies included in 
qualitative synthesis 
Figure 1. PRISMA flowchart of systematic review of studies included in the 
Bayesian network meta-analysis 
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Population (line of 
therapy) 









III or IV BRAF 
V600E mutated 
(1st or 2nd) 
Dabrafenib 150 mg 
po bd 















mg po bd 





DTIC4 338 Reference Reference 29 (9) 
BRF1132201 





(1st, 2nd, 3rd) 
Dabrafenib 150 mg 
po bd + trametinib 2 
mg po od 





Dabrafenib 150 mg 
po bd + trametinib 1 
mg po od 





Dabrafenib 150 mg 
po bd 







III or IV; BRAF 
mutated (1st) 
Vemurafenib 960 
mg po bd + 
cobimetinib 60 mg 
po od 3 weeks on 1 
week off 






mg po bd + placebo 







IIIC or IV; BRAF 
mutated (1st) 
Dabrafenib 150 mg 
po bd + trametinib 2 
mg po od 





Dabrafenib 150 mg 
po bd+ placebo po 
od 








Dabrafenib 150 mg 
po bd + trametinib 2 
mg po od 






mg po bd 









ipilimumab) (1st or 
2nd) 


















III or IV (1st) 2 
Selumetinib 100 mg 
po bd continuously 















Selumetinib 75 po 
bd + DTIC4 





Placebo po bd + 
DTIC4 
46 Reference Reference 12 (26) 
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Table 1 (Continued) 








if BRAF mutated) 
(2nd or further 
Nivolumab 3 mg/kg 
iv every 2 weeks 
272 - - 38 (32) 
Carbotaxol6 or 
DTIC4 








III or IV non-
uveal, BRAF wild 
type (1st) 
Nivolumab 3 mg/kg 
iv every 2 weeks + 
DTIC-placebo 






placebo iv every 2 
weeks 








III or IV; BRAF 
mutated (1st) 
Nivolumab 3 mg/kg 







Nivolumab 1 mg/kg 
+ Ipilimumab 3 
mg/kg iv both 
every 3 weeks 4× 
then Nivolumab 3 










iv every 3 weeks 
4× then nivo-
placebo iv every 2 
weeks 








III or IV (1st) 
Nivolumab 1 mg/kg 
+ Ipilimumab 3 
mg/kg iv every 
3 weeks 4× then 
Nivolumab 3 mg/kg 
iv every 








mg/kg + Placebo iv 
every 3 weeks 4× 
then Placebo iv 
every 2 weeks 
(BRAF wild type) 
37 - Reference 4 (11) 
Nivolumab 1 mg/kg 
+ Ipilimumab 3 
mg/kg iv every 
3 weeks 4× then 
Nivolumab 3 mg/kg 








mg/kg + Placebo iv 
every 3 weeks 4× 
then Placebo iv 
every 2 weeks 
(BRAF mutated) 
10 - Reference 1 (10) 
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BRAFi if BRAF 
mutated (2nd or 
3rd) 
Pembrolizumab 2 
























III or IV (1st or 
2nd) 
Pembrolizumab 10 
mg/kg iv every 2 
weeks 






mg/kg iv every 3 
weeks 






mg/kg iv every 3 
weeks 4x 






III or IV (1st) 
Tremelimumab 10 
mg/kg every 90 
days 







327 Reference Reference 32 (10) 
NCT, National Clinical Trial (NCT) number found on clinicaltrials.gov; N, number of enrolled patients; 
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; BRAFi, BRAF inhibitor; MEKi, 
MEK inhibitor; po, oral; od, once a day; bd, twice a day; iv, intravenously; ipi-placebo, placebo matched to 
ipilimumab; nivo-placebo, placebo matched to nivolumab. 
1Included patients from randomized part (part C) of the trial. 
2BRAF mutation-positive data extracted from subgroup analysis. 
3Data available after systematic review and not included in the meta-analysis. 
4DTIC: Dacarbazine 1000 mg/kg iv every 3 weeks. 
5Paclitaxel: Paclitaxel 175 mg/m2 every 3 weeks. 
6Carbotaxol: Paclitaxel 175 mg/m2 plus carboplatin AUC 5 both iv every 3 weeks. 
7Temozolomide: temozolomide 200 mg/m2/d 5 days ON every 28 days. 
8Carbotaxol: Paclitaxel 225 mg/kg plus Carboplatin AUC 6 both iv every 3 weeks. 
 
2.3.2 Quantitative analysis 
The 16 trials were grouped across eight therapeutic nodes (6849 patients) according 
to type of therapy: chemotherapy, CTLA-4 blockade (CTLA-4i), PD-1 blockade (PD-1i), 
BRAF inhibitors (BRAFi), MEK inhibitors (MEKi), dual BRAF-MEK inhibitors (BRAFi-
MEKi), chemotherapy-MEKi, and dual CTLA-4-PD-1 inhibitors (CTLA-4i-PD-1i). 
Figure 2 describes the network design of treatments’ comparison. All standard 
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chemotherapies (paclitaxel, temozolomide, dacarbazine) were gathered into a single 
therapeutic node (chemotherapy), with analogous collapse for PD-1 drugs (nivolumab and 
pembrolizumab). BRAFi and MEKi results are restricted to BRAF mutated patients across 
all comparisons. The area of the circle in Figure 2 is proportional to the sample size of 
patients enrolled in each node; the width of connecting lines indicates the number of direct 
comparisons within trials. The nodes were organized based on the following groupings:  
- Chemo: chemotherapy; 
- *: MEKi + chemotherapy;  
- **: CTLA-4i-GMCSF;  
- ***: CTLA-4-chemotherapy;  
- Green circles: immunotherapy nodes;  
- Orange circles: BRAFi or MEKi-based nodes;  
- Blue circle: chemotherapy node.  
Number of patients in each node: CTLA-4i: 1172; PD-1i: 1527; CTLA-4i-PD-1i: 
409; CTLA-4-chemotherapy: 250; CTLA-4i-GMCSF: 123; MEKi single agent: 259; 
Chemotherapy: 804; BRAFi single agent: 1390; BRAFi + MEKi: 918; MEKi + 
chemotherapy: 45. Not all trials described all outcomes (Table 1). 
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Figure 2. Network diagram of therapeutic nodes. 
2.3.3 Efficacy 
Three therapies achieved meaningful benefit as compared to chemotherapy: PD-1 
blockade, BRAFi-MEKi combination and BRAFi. As evidenced by comparing the 
prediction and confidence intervals for OS, PFS and RR, study-to-study heterogeneity was 
present, but broadly had little impact on posterior ranking of treatments. 
2.3.4 Overall survival 
OS data were available for 12 (of 16) studies including 4817 patients. The results 
based on traditional pairwise meta-analysis and Bayesian network meta-analysis were 
aligned with no identifiable signal of inconsistency between indirect and direct approaches. 
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Three therapies improved OS when compared to chemotherapy, BRAFi-MEKi 
combination (HR: 0.50; 95% CrI: 0.34–0.74; 95% PrI: 0.31–0.82), PD-1i (HR: 0.52; 95% 
CrI: 0.36–0.75; 95% PrI: 0.32–0.83), and BRAFi (HR: 0.71; 95% CrI: 0.51–0.97; 95% PrI: 
0.46–1.09). PD-1i and BRAFi-MEKi performed similarly (HR: 1.03; 95% CrI: 0.60–1.76; 
95% PrI: 0.56–1.90) with probability of BRAFi-MEKi being superior to PD-1i of 55.8%. 
Both BRAFi-MEKi and PD-1i had high posterior probability of outperforming all 
competitors. Full comparative OS results are provided in Figure 3. Given high probabilities 
of outperforming competitor therapies, for PFS and RR, BRAFi-MEKi combination may 
be optimal for BRAF-mutated patients, whereas PD-1i may be optimal for BRAF wild-
type patients or selected BRAF-mutated patients.  
Despite the lack of OS data for CTLA-4i-PD-1i combination at the time of systematic 
review, PFS and RR data were suggestive that CTLA-4i-PD-1i could also achieve 
meaningful benefit and consequently be a top-ranking option irrespective to BRAF status 
(see below) [34, 57]. 
The results based on traditional pairwise meta-analysis were consistent with the 
results based on the Bayesian network meta-analysis (see Figure 4). Figure 5 displays a 
comparison of the results of the Bayesian network meta-analysis to the corresponding 




Figure 3. Overall survival network meta-analysis 
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Figure 4. Overall survival traditional meta-analysis 
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Figure 5. Overall survival details 
2.3.5 Progression-free survival 
Fifteen trials contributed to the PFS analysis. Worthy of note, the trial comparing 
tremelimumab (CTLA-4i) to chemotherapy provided 6-month time-restricted PFS data 
with tumor assessments done at different time points, every 6 weeks in the dacarbazine arm 
and every 12 weeks in the tremelimumab arm [61]. This study was not included in the PFS 
analysis.  
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Four therapies clearly stood better than chemotherapy: BRAFi-MEKi (HR: 0.22; 
95% CrI: 0.16–0.31; 95% PrI: 0.14–0.34), CTLA-4i-PD-1i (HR: 0.39; 95% CrI: 0.25–0.6; 
95% PrI: 0.23–0.66), BRAFi (HR: 0.39; 95% CrI: 0.29–0.52; 95% PrI: 0.26–0.59), and 
PD-1i (HR: 0.5; 95% CrI: 0.4–0.64; 95% PrI: 0.34–0.73). Single agent PD-1i and dual 
CTLA-4i-PD-1i, both outperformed CTLA-4i with corresponding posterior probability of 
99.5% (HR: 0.53; CrI: 0.42–0.68) and 99.9% (HR: 0.42; CrI: 0.3–0.57). CTLA-4i had 
similar performance to chemotherapy (HR: 0.94; CrI: 0.67–1.31).  
Dual BRAFi-MEKi yielded the best PFS results with a 96.2% posterior probability 
of outranking the remaining options, even when compared to CTLA-4i-PD-1i (HR: 0.56; 
CrI: 0.33–0.97). CTLA-4i-PD-1i and BRAFi stood close as next options (CTLA-4i-PD-1i 
vs. BRAFi HR: 1.00; 95% CrI: 0.6–1.67), both probably above single agent PD-1i. Full 
comparative PFS results are provided in Figure 6. Figure 7 contains the results from the 
traditional meta-analysis. Figure 8 shows that the estimates from the network meta-analysis 
are consistent with the published studies.  
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Figure 6. Progression-free survival network meta-analysis 
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Figure 7. Progression-free survival traditional meta-analysis 
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Figure 8. Progression-free survival details 
2.3.6 Response rate 
RR data were available for all studies. Bearing in mind that response under CTLA-
4i can be a late event, we included the tremelimumab versus chemotherapy trial in this 
analysis. Four therapies led to meaningful benefit (OR ≥ 3.0 and probability better ≥ 95% 
vs. chemotherapy): BRAFi-MEKi (HR: 19.76; 95% CrI: 10.45–37.35; 95% PrI: 9.19–
42.52), BRAFi (HR: 10.78; 95% CrI: 6.24–18.63; 95% PrI: 5.4–21.48), CTLA-4i-PD-1i 
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(HR: 7.25; 95% CrI: 4.09–12.86; 95% PrI: 3.57–14.7), and PD-1i (HR: 4.32; 95% CrI: 
3.07–6.09; 95% PrI: 2.52–7.45). Full comparative RR results are presented in Figure 9. 
Results from traditional meta-analysis are given in Figure 10, and results from the network 
meta-analysis are compared to published estimates in Figure 11. 
Dual BRAFi-MEKi therapy topped best with at least 97.1% posterior probability of 
being superior to any other treatment: CTLA-4i-PD-1i (OR: 2.73; CrI: 1.18–6.3), CTLA-
4i (OR: 17.2; CrI: 8.31–35.58), PD-1i (OR: 4.57; CrI: 2.24–9.31), MEKi (OR: 8.56; CrI: 
3.32–22.04), and BRAFi (OR: 1.83; CrI: 1.37–2.45). For BRAF-mutated patients, the 
second best option was BRAFi. CTLA-4i-PD-1i dual checkpoint blockade had a 94.3% 




Figure 9. Response rate network meta-analysis 
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Figure 10. Response rate traditional meta-analysis 
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Figure 11. Response rate details 
2.3.7 PD-L1 expression and BRAF mutational status as biomarkers of response to 
immunotherapy 
The Bayesian network meta-analysis failed to identify any relevant impact of BRAF 
mutation status on efficacy of immunotherapy treatments for OS, PFS, or RR in all subsets 
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sought. The hazard ratios, 95% credible and predictive intervals of BRAF-mutated and 
wild-type patients were superimposable, which negates any role of BRAF status as a 
predictor of benefit of immunotherapy (Table 2). The posterior probability that BRAF+ 
patients had better efficacy of immunotherapies relative to chemotherapy, [P(BRAF+ 
better)] was from 21% to 50% for OS, 17% to 51% for PFS, and from 16% to 61% for RR. 
Also, 95% CrIs failed to show any difference according to BRAF mutation status. Results 
were similar for data selection containing first-line studies with results stratified by BRAF 
status; credible and predictive intervals did not show evidence of a difference between 
BRAF wild-type and mutation positive patients in terms of relative efficacy of 
immunotherapies. As all trials testing BRAFi limited the enrollment of BRAF+ patients, 
BRAF status was disregarded from the analysis henceforth 
Two immunotherapy trials provided information on outcomes according to PD-L1 
status [34, 57]. As the definitions of positive and negative tumor PD-L1 expression as well 
as the laboratory methods used to ascertain them were not homogenous across the two PD-
1 trials (Nivolumab: at least 5% of tumor cells with PD-L1 at any intensity at the 
membrane; Pembrolizumab: >1% tumor cells with membranous PD-L1 expression), we 
accepted the trials’ original cutoffs.   
For both PFS and RR, the Bayesian network meta-analysis failed to show any 
relevant impact of PD-L1 status on efficacy of CTLA-4i-PD-1i, PD-1i, or CTLA-4i. The 
hazard ratios and 95% CrIs of PD-L1 positive and PD-L1 negative patients overlapped, 
failing to identify any difference according to PD-L1 status (Table 3). The posterior 
probability that PD-L1 positive patients had better efficacy under CTLA-4i-PD-1i, PD-1i, 
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or CTLA-4i, (probability PD-L1+ better) was from 44% to 56% for PFS, and 62% to 83% 
for RR. 
Table 2. Comparison of treatments according to BRAF mutation status 
 




This meta-analysis synthesizes the wealth of information on immunotherapy and 
BRAFi/MEKi for advanced melanoma, producing a ranking of the drugs currently 
available. The network approach attempts to circumvent the absence of direct comparisons 
among the many available options, notably the comparison of immunotherapy to BRAF-
MEK inhibition and among immunotherapies. The present meta-analysis suggests that dual 
BRAFi-MEKi is the most effective in improving OS, PFS, and RR of BRAF-mutated 
patients, outperforming other treatments. 
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Among the BRAF-MEK axis inhibition options, single-agent BRAFi ranked below 
BRAFi-MEKi combination, but could still offer higher benefits than single MEKi. These 
findings may prompt inquiry into how to manage dose reduction of MEKi and BRAFi in 
the event of toxicities likely to be caused by both drugs. However, clinically relevant this 
question is, it is beyond the scope of our study to provide such practical guidance. 
Appraising the PFS and RR scenarios, it was conceivable that BRAFi-MEKi would 
dominate them, as BRAF-MEK inhibition was already known to produce frequent and 
rapid responses, whereas immunotherapy may take longer to produce sustained tumor 
shrinkage and even lead to unconventional response patterns not properly captured by the 
standard response assessments [39, 68, 69]. CTLA-4i epitomized the immune response 
pattern: failed to improve PFS and RR when compared to chemotherapy, but prolonged 
OS, as the original trials suggested [36, 61]. Our findings underscore the perception that, 
standard PFS assessment may not be the best way to capture anti-tumor activity of 
immunotherapy. Nevertheless, it is noteworthy that dual BRAFi-MEKi also stood as the 
best option with regard to OS, even when compared to single-agent PD-1i. 
Notwithstanding the BRAF-MEK inhibition dominance, PD-1 blockade still ranked 
high in terms of OS, PFS, and RR. Hence, PD-1i may be an attractive option for BRAF 
wild-type patients and even for BRAF-mutated patients, as it ranked in second to BRAFi-
MEKi. OS results for combined CTLA-4-PD-1 immune checkpoint inhibition are not yet 
mature and longer follow-up may change the order of top-ranked therapies. Some very 
recent results have started to become available with promising long-term survivorship with 
dual immune checkpoint blockade [67]. Those findings seem to embody the preliminary 
reports of prolonged disease control under immunotherapy [13]. 
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We could not confirm the role of PD-L1 as a biomarker of response to PD-1i-based 
therapy. As currently tested, tumor PD-L1 expression did not better inform the patient 
selection for PD-1-based therapy, both PD-L1 positive and negative patients derived 
substantial benefit from PD-1-based therapy. This finding somewhat diverged from the 
realms of other tumors, showcasing the particular features of immune response within each 
tumor type [70]. Also, our results failed to show any impact of BRAF status on response 
to PD-1 therapy, confirming previous findings [71]. 
Several issues may be implicated on the lack of surrogacy of PD-L1 expression. The 
simplest one would be statistical power constrained by a small sample size. This indeed 
could have played a role, however, more than 800 patients—evenly divided between PD-
L1 positive and negative— provided data for this analysis. Another possibility would be 
the use of inadequate cutoffs. To properly assess this, individual patient data would be 
required. However, even if such data were available, the different antibodies and 
techniques would require careful consideration. Harmonization of laboratory methods 
should be enacted first, as is already occurring in lung cancer with the different PD-1/PD-
L1 agents. 
Lastly, baseline PD-L1 expression at a single tumor site may not be capable of fully 
capturing the complexity of anti-PD-1-led orchestration of immune system dynamics. It is 
conceivable that resetting a whole system—in the case of immune system—might be 
multilayered and continuously changing. 
The quest for excellent patient selection is key. Better patient selection transcends 
optimizing clinical outcomes. It can improve financial resource allocation, a real-world 
 38 
hurdle to be crossed when new technologies are under consideration. Furthermore, 
identifying the most likely patients for immunotherapy will spare the nonresponders from 
fairly toxic therapies. The results of cooperative work on other tumors may enhance our 
understanding on this important topic [72-76]. 
Given the number of therapeutic options currently available for advanced melanoma, 
the sequencing of drugs is another crucial question. The wealth of information organized 
by this meta-analysis may shed light on the long-term therapeutic plan for melanoma 
patients. These nuances of clinical management are yet to be defined. However, we believe 
that clinicians will now be better informed for the decision-making process. Definitive 
results on sequencing of the various therapeutic options will add to the knowledge base 
[77, 78]. 
A major clinical concern is the effectiveness of immunotherapy after progressing 
under previous BRAF-MEK treatment. Two immunotherapy trials enrolled patients who 
had progressed while on BRAF-targeted therapy [33, 62]. No sign of loss of efficacy was 
identified with the use of PD-1 drug among this group of patients as compared to BRAF 
therapy-naïve patients. Such findings must be further validated and the opposite drug order 
also appraised, the latter being the question of active trials [78]. 
This meta-analysis faced several shortcomings inherent to the methodology applied. 
We had no access to individual patient data, precluding a more detailed appraisal of 
outcomes and patients’ characteristics. This is especially true for assessment of the role of 
PD-L1 expression, volume of disease, and presence of other known prognostic markers 
[79, 80]. We concentrated on efficacy foregoing analysis of toxicity, another major 
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practical concern on clinical grounds. The different cutoffs used for defining PD-L1 status 
hindered a more robust analysis of its relevance. The absence of overall survival data for 
CTLA-4-PD-1 trials is a major shortcoming and hopefully more data will become available 
in the near future [67]. Also, for the sake of simplicity, we analyzed all drugs in the same 
therapeutic node as identical (for instance tremelimumab and ipilimumab as CTLA-4i 
prototypes). Furthermore, the duration of response could not be formally assessed as the 
original trials lacked enough information for a comprehensive appraisal. 
Another concern was the publication and trial quality biases. We sought the most 
relevant databases in order to collect all published and presented trials so far, checked their 
references and references from relevant reviews and followed Cochrane′s guidelines on the 
topic. Also, we preplanned the inclusion of BRAFi or immunotherapy trials in order to 
concentrate on the most promising therapies; hence, some randomized trials testing other 
targeted therapies, such as sorafenib, oblimersen, or endothelin inhibitors were not meta-
analyzed. Trials enrolling personalized therapy to other targets, such as NRAS-mutant 
tumor, were not included [81]. With regard to the quality of trials included, nearly all trials 
were ascribed as high quality according to the Cochrane risk of bias tool, with the lack of 
placebo as the commonest source of likely bias. 
Furthermore, it is conceivable that gathering different drugs with different doses and 
regimens in the same node could lead to heterogeneity, and some heterogeneity was found 
among the several comparisons made. Nevertheless— and most importantly—direct 
comparison results were in line with the network results and the impact of heterogeneity 
on the ranking of therapy options was minimal. 
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 In spite of all those shortcomings listed above, we were able to formally compare 
different therapies and provide a clear rank of efficacy of the many available options for 
advanced melanoma. Abstracting all this sizeable amount of information, combined 
BRAFi-MEKi-targeted therapy seems to be a sound option at the present—even in light of 
emerging results of immune therapy—for BRAF-mutant patients. Longer follow-up in dual 
immune checkpoint trials coupled with further analysis of immune markers have the 
potential to further enhance outcomes in advanced melanoma. 
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CHAPTER 3. ABIRATERONE OR ENZALUTAMIDE IN 
CASTRATION-RESISTANT PROSTATE CANCER: INDIRECT 
COMPARISON 
3.1 Introduction 
Prostate cancer is the most commonly diagnosed cancer and the second leading 
cause of cancer-related deaths among men in developed countries [82]. In the United 
States, according to the National Cancer Institute’s Surveillance Epidemiology and End 
Results (SEER) database, prostate cancer prevalence in 2012 was estimated at 
approximately 890 per 100,000 men. Approximately 14.0% of men will be diagnosed with 
prostate cancer at some point during their lifetime.  
A significant majority of prostate cancers are diagnosed at an early-localized stage; 
however, some patients will relapse with disseminated disease while others are diagnosed 
with advanced cancer at initial presentation [83].  
Prostate cancer cells are dependent on androgen receptor (AR) signaling for growth 
and survival. Androgen-deprivation therapy is the standard of care for advanced or 
metastatic prostate cancer, and has been for decades [84-87]. Even though more than 90% 
of prostate cancer patients initially respond to androgen deprivation therapy; many tumors 
become refractory and castration-resistant with time.  
Multiple active treatment modalities have been developed for men with advanced 
castration-resistant prostate cancer (CRPC) with the aim of prolonging survival, 
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minimizing complications, and maintaining or improving quality of life. These agents have 
distinct modes of action and include chemotherapeutic agents, such as docetaxel and 
cabazitaxel, the immunotherapeutic agent, sipuleucel-T, the bone targeting alpha-emitting 
radionuclide, radium-223 chloride, as well as the novel androgen receptor (AR) pathway 
inhibitors abiraterone acetate (abiraterone) and enzalutamide [88-95].  
The development of novel anti-androgens and androgen synthesis inhibitors as a 
result of research efforts over the past decade show that CRPC remains dependent on AR 
function for growth by evolving multiple mechanisms to activate receptor signaling such 
as ligand independent activation of AR,  verexpression of the AR receptor, gain of function 
mutations in AR, and upregulation of androgen biosynthesis enzymes [96].  
Abiraterone acetate (AA), a pro-drug of abiraterone, is a selective irreversible 
inhibitor of the products of the CYP17 gene (including both 17,20-lyase and 17- alpha-
hydroxylase), and thereby blocks synthesis of androgens in tumor as well as in the testis 
and adrenal glands. Enzalutamide is an orally administered, potent next-generation 
antiandrogen agent that acts at multiple sites in the androgen receptor signaling pathway, 
including blocking binding of androgen to the androgen receptor, inhibition of nuclear 
translocation of the androgen receptor, and inhibition of the association of the androgen 
receptor with nuclear DNA. Unlike abiraterone, concurrent treatment with steroids is not 
required.  
AA and enzalutamide have both been investigated and shown to prolong overall 
survival in large phase III trials in both the pre- and post-docetaxel settings [91-94]. Large-
scale, prospective randomized trials testing the optimal sequencing of these treatments 
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have not yet been reported, nor have the two agents been compared head to head against 
each other in a prospective randomized fashion. There is some evidence from a number of 
small retrospective cohort studies suggesting limited activity of these agents when used in 
a sequential fashion either before or after docetaxel chemotherapy in advanced CRPC [97-
107]. Development of predictive biomarkers to facilitate the selection of patients for a 
specific therapy or sequence of therapies is the focus of ongoing efforts. Recently, the AR-
V7 splice variant, a truncated isoform of the AR that lacks the binding domain of both 
enzalutamide and AA, was shown to be associated with resistance to both agents as 
evidenced by inferior PSA50 response rates, PFS and OS [108]. AA and enzalutamide 
differ in the use of prednisone and in the incidence of toxicities, which can be used in the 
decision-making process either for upfront and sequential therapy. 
To assist practicing clinicians in decision-making, we performed two analyses, a 
comparative effectiveness study using available evidence from randomized studies and a 
sequencing assessment using additional available evidence from observational studies of 
enzalutamide and AA in a post-AR pathway inhibitor setting. Indirect meta-analyses are 
often used to provide preliminary guidance when head to head evidence is not available. 
In the comparative effectiveness study, enzalutamide and AA were compared 
indirectly in terms of OS, radiographic PFS, time to PSA progression, PSA response rates 
(RR), and adverse events in both the pre-docetaxel and post-docetaxel setting [91-94]. In 
the sequencing assessment, the treatment ordering of enzalutamide and AA are compared 
in terms of OS in the post-docetaxel setting, using both randomized and observational 
evidence [92, 93, 97-101, 103, 104, 106]. 
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3.2 Methods 
3.2.1 Comparative Effectiveness 
Indirect meta-estimates were generated in the context of a Bayesian hierarchical 
model with study specific efficacy estimates meta-analyzed on the log (of hazard or odds 
ratio) scale similarly to the approach found in section 2.2.5. The primary endpoint, OS, and 
secondary endpoints, radiographic PFS, time until PSA progression, and PSA response 
rate, were modeled as jointly multivariate Gaussian with mean depending on each study’s 
treatment contrast and variance-covariance matrix composed as the sum of a diagonal 
matrix of within study variances and a full dimensional between study variance-covariance 
matrix. Treatment effects considered were enzalutamide relative to placebo in the pre-
docetaxel setting, AA relative to placebo in the pre-docetaxel setting, modification of both 
enzalutamide and AA effects in the post-docetaxel setting, and modification of AA effects 
due to the addition of prednisone in the placebo arm in both the pre- and post-docetaxel 
settings. A Bayesian perspective is appropriate from a decision making (choosing the best 
treatment in a particular context) point of view, and allows seamless incorporation of 
sources of uncertainty. The primary measure of efficacy was posterior probability 
enzalutamide outperforms AA with prednisone in terms of OS on average. Secondary 
measures of efficacy were posterior probability enzalutamide outperforms AA with 
prednisone in terms of OS in an individual study setting, as well as hazard and odds ratios 
along with 95% credible and predictive intervals. Both pre- and post-docetaxel settings 
were of interest. 
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Throughout, priors were selected to reflect the range of realistically plausible 
parameter values. In particular, priors for enzalutamide and AA relative to placebo in the 
pre-docetaxel setting placed 95% of their mass on hazard ratios between 1/10 and 10 (odds 
ratios between 1/400 and 400), priors for the modification of both enzalutamide and AA 
effect in the post-docetaxel setting placed 95% of their mass on hazard ratios between 
1/1.25 and 1.25 (odds ratios between 1/1.5 and 1.5), and priors for the modification of AA 
effect due to the addition of prednisone in the placebo arm placed 95% of their mass on 
hazard ratios between 1/1.1 and 1.1 (odds ratios between 1/1.25 and 1.25). Priors for within 
study variances were taken as inverse gamma with mean equal to the reported (or 
recalculated) standard errors and variance proportional (conservatively) to each study’s 
total number of deaths. Priors for between study variances were taken as uniform on (0, 
0.175), allowing high prior probability of up to twofold differences in hazard and odds 
ratios across individual study settings, and priors for correlations between endpoints were 
taken as uniform on (0, 1) for between survival endpoints and uniform on (-1, 0) for 
between survival endpoints and response. A sensitivity analysis was performed by 
increasing the spread of the prior mass by approximately sevenfold for the priors for 
treatment effects and between study variances. Adverse event rates were summarized 
separately along with Wilson confidence intervals for each trial [109]. 
3.2.2 Sequencing Assessment 
Sequencing of enzalutamide and AA was assessed in the context of exponential 
survival models, informed by Bayesian meta-analyses with between and within study 
variance components. First, OS and PFS time to event data was extracted from published 
Kaplan-Meier curves, along with numbers at risk and censoring times, if available. Plots 
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were digitized using WebPlotDigitizer [110], and a custom built R [45] code was used to 
extract the raw time to event dataset. Censored data could only be characterized up to an 
interval between actual event times if censoring times were not provided. In this case, 
censoring times were taken at the lower bound of possible censoring times to provide a 
conservative estimate of information content. Then, for each time to event dataset, an 
exponential distribution was fit. In particular, the (monthly) rate parameter along with 
accompanying standard error were estimated for each time to event dataset. These rates 
were then meta-analyzed using a Bayesian model with between and within study variance 
components. Uninformative priors were used for the mean treatment effects by placing the 
mean at 0 and the within-study variance at 100 on the log hazard scale. A weakly 
informative prior was used for the between-study variance which placed 95% of the prior 
probability on hazard to varying up to two-fold across studies.  
For constructing the sequencing assessment, rates of interest were OS and 
progression in the initial AR pathway inhibitor setting and OS in the post-progression after 
AR pathway inhibitor setting. Notably, PFS time is the minimum of OS and progression 
time and, in the context of the exponential model, the rate corresponding to the progression 
event is the difference between the PFS and OS rates. Data sources for the sequencing 
assessment were both randomized and observational. Randomized controlled data from the 
comparative effectiveness study was utilized to inform the initial AR pathway inhibitor 
setting, while observational data was utilized to inform the post-progression after AR 
pathway inhibitor setting.  
The two sequencing strategies enzalutamide then AA and AA then enzalutamide, 
were compared by, separately for each strategy and for each of 10,000 draws from the 
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posterior distribution of rates, generating 5,000 initial AR pathway inhibitor OS and 
progression times and 5,000 post-progression after AR pathway inhibitor OS times. For 
each of these 5,000 sets of times, if the initial (strategy specific) AR pathway inhibitor 
progression time was before the OS time, then the strategy OS time was the sum of the 
initial AR pathway inhibitor progression time and the post-progression after AR pathway 
inhibitor OS time. On the other hand, if the initial (strategy specific) AR pathway inhibitor 
progression time was after the OS time, then the strategy OS time was simply the initial 
AR pathway inhibitor OS time. Based on each of these size 5,000 datasets (one dataset for 
each of 10,000 posterior draws) of OS times from initiation of first AR pathway inhibitor, 
several metrics of comparison were computed, HRs, median survival times, and 
probabilities of one- and two-year survival. Each of these metrics of comparison was 
summarized across the posterior as posterior median along with CrI. 
3.3 Results 
3.3.1 Comparative Effectiveness 
Characteristics and efficacy summaries of studies included in the comparative 
effectiveness study are summarized in Table 4. 
3.3.2 Overall Survival 
There was weak evidence that enzalutamide outperforms AA with prednisone in 
terms of OS in the predocetaxel setting with posterior probability enzalutamide better than 
AA with prednisone on average of 0.68 and posterior probability enzalutamide better than 
AA with prednisone in individual study of 0.64 (HR 0.91, 95% Credible Interval (CrI) 
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0.62–1.35, 95% Predictive Interval (PrI) 0.55–1.53). Similarly, there was weak evidence 
that enzalutamide outperforms AA with prednisone in terms of overall survival in the 
postdocetaxel setting with posterior probability enzalutamide better than AA with 
prednisone on average of 0.70 and posterior probability enzalutamide better than AA with 
prednisone in individual study of 0.66 (HR 0.90, 95% CrI 0.61–1.33, 95% PrI 0.54–1.50). 
Comparative effectiveness summarized in Table 5 and Figure 12. 
3.3.3 Secondary Endpoints 
There was strong evidence that enzalutamide outperforms AA with prednisone in 
terms of secondary endpoints radiographic PFS, time until PSA progression, and PSA 
response rate in both the pre- and post-docetaxel settings, with posterior probabilities 
enzalutamide better than AA with prednisone both on average and in individual studies 
exceeding 0.97. Comparative effectiveness summarized in Table 5 and Figure 12.  
Rates of adverse events grade ≥3 for enzalutamide versus placebo, pre-docetaxel 
were 46% versus 37% (𝑃 = 0.001), for abiraterone/prednisone versus placebo/ 
prednisone, pre-docetaxel were 48% versus 42% (𝑃 = 0.057), for enzalutamide versus 
placebo, postdocetaxel were 45% versus 53% (𝑃 = 0.012), and for abiraterone/prednisone 
versus placebo/prednisone, post-docetaxel were 23% versus 19% (𝑃 = 0.146). All 
reported adverse events are summarized in Table 18 in Appendix B. 
3.3.4 Sensitivity Analysis 
The results of the sensitivity analysis were broadly similar to the main analysis in 
both the pre- and post-docetaxel setting, with strong evidence of benefit for enzalutamide 
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relative to AA with prednisone in terms of secondary endpoints radiographic PFS, time 
until PSA progression, and PSA response rate. However, evidence of benefit for 
enzalutamide relative to AA with prednisone in terms of OS was very weak. Sensitivity 
analysis results summarized in in Appendix B. 
3.3.5 Sequencing Assessment 
Characteristics and monthly event rates of studies included in the sequencing 
assessment are summarized in Table 20 in Appendix B. Unfortunately, there was not 
sufficient data to perform a sequencing assessment in a pre-docetaxel setting. 
Our analysis provides evidence that in the post-docetaxel setting the AA then 
enzalutamide strategy may be associated with longer OS time than the enzalutamide then 
AA strategy. In particular, respective median survival times for the AA then enzalutamide 
strategy and the enzalutamide then AA strategy were estimated at 21.3 months (95% CrI 
16.6-28.9) and 14.7 months (95% CI 11-21.2), with posterior HR 0.66 (95% CrI 0.43-1.17) 
and posterior probability AA then enzalutamide better than enzalutamide then AA of 0.94. 
Results of sequencing analysis are summarized in Table 6. 
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11.2 3.6 6.6 5.5% 
aConcomitant administration with prednisone was allowed but not required; 
bconcomitant administration with prednisone; 
cresponse rate defined as PSA decline > 50%;  
ddenominator (enzalutamide) was 396, denominator (placebo) was 381;  
edenominator (enzalutamide) was 731, denominator (placebo) was 330. 
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0.68 
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Ratio < 1a 
0.70 
(0.66) 
0.99 (0.97) 1.00 (1.00) 
1.00 
(1.00)b 
aPosterior probability (predictive probability), bOdds ratio for response. 
 
Table 6: Sequencing assessment for AA then enzalutamide strategy and the 
enzalutamide then AA strategy in a post-docetaxel setting 
 AA then Enzalutamide Enzalutamide then AA 
Posterior HR 0.66 (95% CI 0.43-1.17) - 
Posterior Prob. HR < 1 0.94 - 
Median Survival Time (Months) 21.3 (95% CI 16.6-28.9) 14.7 (95% CI 11-21.2) 
Posterior Prob. One Year Survival 0.71 (95% CI 0.62-0.79) 0.58 (95% CI 0.47-0.7) 
Posterior Prob. Two Year Survival 0.45 (95% CI 0.34-0.57) 0.29 (95% CI 0.1-0.45) 
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Figure 12. Individual study estimates and comparative meta-estimates for efficacy 
outcomes for enzalutamide vs. abiraterone in the pre- and post-docetaxel settings 
3.4 Discussion 
Recent availability of multiple effective agents tested in randomized trials has 
added complexity to the decision-making algorithm in advanced prostate cancer. The lack 
of randomized head-to-head comparison data between AA and enzalutamide makes it 
difficult to choose the optimal first-line treatment either pre- or post-chemotherapy in 
patients with advanced or metastatic CRPC. 
We found that there is only weak evidence that enzalutamide is better than AA with 
prednisone in terms of OS in both the pre- and post-docetaxel setting. However, we found 
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strong evidence that enzalutamide outperforms AA with prednisone in terms of secondary 
endpoints radiographic PFS, time until PSA progression, and PSA response rate in both 
the pre- and post-docetaxel settings. Grade 3 or worse adverse event rates were similar 
between AA and enzalutamide in a pre-docetaxel setting, while there was some evidence 
that AA may have a lower grade 3 or worse adverse event rate than enzalutamide in a post-
docetaxel setting (see Table 18). Therefore, clinicians could consider enzalutamide over 
AA and steroid when looking for a robust PSA response, improvement in PFS and time to 
PSA progression. The choice of either drug should also be tailored based on patient 
preferences, requirement of concomitant administration of steroids, co-morbidities and 
drug accessibility. 
A sequencing assessment of available published trials provided some evidence that 
in a post-docetaxel setting, AA then enzalutamide upon progression may be associated with 
longer OS time than enzalutamide then AA upon progression. This finding in the 
sequencing assessment seems contradictory to the comparative effective analysis. There 
are a few potential explanations. First, there is the possibility that treatment with 
enzalutamide may adversely impact subsequent effectiveness of AA more than AA 
treatment adversely impacts subsequent treatment with enzalutamide. Another possibility 
is that, since evidence suggests that enzalutamide may extend time to progression without 
extending survival time, patients given initial enzalutamide are more likely to die before 
switching to AA. On the other hand, evidence suggests that patients initiated on AA are 
more likely to progress, and be switched to enzalutamide, before dying. Still another 
possibility is that the utilization of non-randomized data has led to an incorrect conclusion. 
Further evidence on sequencing is needed. 
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Our analysis becomes even more relevant with recent publication of three 
randomized clinical trials that suggest that androgen deprivation therapy (ADT) plus early 
docetaxel-based chemotherapy improves progression-free and overall survival in men with 
metastatic castration-sensitive prostate cancer compared with androgen deprivation 
therapy alone in high risk patients [111-113]. Enzalutamide may perform better as 
compared to AA with prednisone in these patients upon progression. 
There is also some evidence from a number of small retrospective cohort studies 
suggesting limited activity of these agents when used in a sequential fashion either before 
or after docetaxel chemotherapy in advanced CRPC [97-107]. Development of predictive 
biomarkers to facilitate the selection of patients for a specific therapy or sequence of 
therapies is the focus of ongoing efforts. Recently, the AR-V7 splice variant, a truncated 
isoform of the AR that lacks the binding domain of both enzalutamide and AA, was shown 
to be associated with resistance to both agents as evidenced by inferior PSA50 response 
rates, PFS, and OS [108]. Prospective combination and sequence studies using both these 
active agents to target the androgenbased pathway in advanced CRPC are ongoing [78, 
114, 115]. Data from a small prospective phase I/II study in 60 men was presented during 
a recent ASCO meeting [116]. Preliminary results show safety and no untoward 
pharmacokinetic interactions of this combination. 
The comparative effectiveness study and sequencing assessment presented here 
have a number of limitations and strengths. Both are limited by the indirect nature of 
comparisons between AA and enzalutamide, which rely on the quality of between study 
variance component estimates and a lack of systematic interaction between individual 
study characteristics and treatment efficacy. Further, lack of individual patient data 
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precludes detailed identification of sources of study-to-study heterogeneity. The 
sequencing assessment is further limited by the inclusion of observational data, for which 
a causal link between treatment and outcomes cannot be established concretely due to 
various forms of confounding. On the other hand, all included studies were well-executed 
with objectively defined endpoints. There was no evidence of publication bias. The 
Bayesian approach is well-adapted to choosing between treatments with no a priori 
preference. In particular, the posterior probability that one treatment is better than the other 
summarizes the chance, conditional on the data, that one treatment outperforms the other. 
The posterior hazard ratio estimates, along with confidence and predictive intervals, 
indicate how much better might be reasonably expected. In contrast, a traditional 
hypothesis testing perspective is biased towards the null hypothesis, in a sense. In the 
absence of evidence strong enough to refute a pure sceptic, the null hypothesis is selected. 
On the whole, this comparative effectiveness study represents a high-quality synthesis of 
best-available evidence on the comparison of first-line AA and enzalutamide. 
3.5 Conclusions 
We sought to compare indirectly the effectiveness of abiraterone acetate and 
enzalutamide in advanced CRPC. Our results show that in a pre-docetaxel setting, 
enzalutamide may be a better drug than AA with prednisone in terms of radiographic PFS, 
time until PSA progression, and PSA response rate. In a post-docetaxel setting, 
comparative effectiveness analysis showed that enzalutamide may outperform AA with 
abiraterone in terms of secondary end points. The results of our analyses may help guide 
clinicians in making best treatment decisions with their patients. Prospective randomized 
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trials are eagerly awaited to provide insight on the optimal treatment sequence and 
combinations in this patient population.  
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CHAPTER 4. COST-EFFECTIVENESS OF PEMBROLIZUMAB 
AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL 
CELL LUNG CANCER 
4.1  Introduction 
In the last two decades, systemic therapy has brought meaningful clinical 
improvements for non-small cell lung cancer (NSCLC) patients, more than doubling life 
expectancy of patients with metastatic disease. Precision medicine and targeted therapy 
have become a reality responsible for increasingly high response rates and prolonged 
disease control for carefully selected patients [117-121]. Notwithstanding these gains, lung 
cancer remains the most common cause of cancer-related death, claiming more lives than 
breast, prostate, and colon cancer combined [122-124]. Patients lacking actionable targets 
- the majority - or those who inevitably progress after personalized therapy still rely upon 
palliative chemotherapy, with median overall survival not exceeding 16 months [123, 125, 
126]. 
New therapies are urgently required and immunotherapy has shown enormous 
potential to further improve prognosis for lung cancer patients. With elevated neo-antigen 
expression and active mechanisms of immune surveillance evasion, lung cancer is an ideal 
setting for current PD-1, PD-L1, and CTLA-4 therapies [127, 128]. Recently, several PD-
1, PD-L1, and CLTA-4 drugs have reached late phase development for lung cancer, in a 
quest for betterment of prognosis and patient selection [21, 129-131]. 
 58 
Some immunotherapies have received FDA and EMA approval in record time due 
to strong clinical results, with superior, and for some patients durable, survival and more 
tolerable side effects. These results have largely reset standard management of advanced 
NSCLC. Nevertheless, there is a price tagged to these breakthrough treatments that cannot 
be overlooked [132]. 
Analysis of cost-effectiveness of new therapies is imperative to ensure appropriate 
and sustainable use of advanced targeted treatments in NSCLC. The current study 
investigates cost-effectiveness of pembrolizumab treatment for previously untreated 
patients with advanced NSCLC and PD-L1 expression in ≥50% of tumor cells. 
4.2 Materials and Methods 
4.2.1 Data 
Overall survival (OS) and progression-free survival (PFS) time-to-event data were 
extracted from published Kaplan-Meier (KM) curves, numbers at risk, and censoring times 
from the KEYNOTE-024 study. In brief, KEYNOTE-024 compared platinum-doublets 
versus pembrolizumab as first-line therapy for EGFR wild-type, ALK non-translocated, 
chemo-naive advanced lung cancer patients whose tumors expressed PD-L1 in ≥50% of 
cancer cells [20, 133]. The most up to date KM curves [133] for OS and PFS were digitized 
using WebPlotDigitizer [110], and raw time-to-event data was recovered by inverting the 
KM equations with a custom-built R code, extending techniques in Guyot et. al [134]. 
Details on frequency and severity of side effects for both intervention arms were also 
abstracted. We examined the quality of data recovery. 
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4.2.2 Bayesian survival and progression model 
The distributions of OS and PFS times were modeled using a Bayesian semi-
parametric framework. Specifically, we modeled discrete-time event probabilities across 
the time-line up to last follow-up time using a hierarchical Dirichlet Process (DP). The tail 
of the survival distribution (after last follow-up time) was modeled using a Weibull 
distribution. 
The non-parametric nature of the Dirichlet process is well-suited for modeling the 
survival function as survival distributions are in general unlikely to follow a parametric 
family [135]. Bayesian nonparametric inference offers relatively new class of methods. 
There has been an increased interest in nonparametric approaches to analyzing survival 
distributions due to their considerable degree of flexibility compared to parametric 
alternatives. The development of Markov chain Monte Carlo (MCMC) techniques has 
further facilitated the success of Bayesian nonparametric inference.  
One of the seminal works in the field is a paper published in Annals of Statistics in 
1974 by Ferguson [136], who proposed the Dirichlet process as an approach to analyzing 
nonparametric problems from a Bayesian viewpoint. An important result is that if a sample 
is obtained from a mixture of Dirichlet processes, the posterior distribution of the process 
is again a mixture of Dirichlet processes [137]. Later in 1976, Susarla and Van Ryzin [138] 
initiated the modern day nonparametric Bayesian analysis of survival data in medical 
studies with right censored observations. They derived the Bayes estimator of the survival 
function under the Dirichlet process prior. Blum and Susarla [139] showed that the 
posterior survival distribution is a mixture of Dirichlet processes.  
 60 
In 2006, Teh et al [140] extended the ordinary Dirichlet process for accommodating 
and modeling heterogenous groups of data. They introduced the hierarchical Dirichlet 
process. The model pools directly samples of survival data arising from different 
heterogenous groups, and lets clusters flexibly borrow information across groups. This 
approach avoids assumptions about the shape of the survival distributions, allows 
incorporation of censored data, and accommodates study-to-study heterogeneity. 
Furthermore, the DP model is particularly well-suited to situations where relative efficacy 
measures such as hazard and odds ratios are not sufficient, such as cost-effectiveness 
analyses requiring patient-level disease trajectories as a basic ingredient. 
The DP model was constructed by modeling each observed event time as a 
multinomial variable indicating the time interval within which the corresponding event 
occurred. Time up to last follow-up was discretized into one-month intervals. The 
parameters (probability event occurs within each time interval) underlying the multinomial 
distributions were modeled as a study-specific Dirichlet distribution. Right-censored 
observations were also modeled as multinomial variables, with several tail categories and 
corresponding parameters aggregated. For example, if an observation was right-censored 
at 10 months, then it is known that the event occurred at some time after 10 months. The 
corresponding multinomial distribution would have all the categories >10 months 
combined into a single category, with the probability of the combined category equal to 
the sum of its component probabilities. 
The study-specific Dirichlet distribution describing probabilities of events in each 
time interval was in turn modeled as a deviation from an overall Dirichlet distribution. In 
particular, the study-specific time interval probabilities equaled the overall Dirichlet 
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probabilities on average, but with study-to-study heterogeneity controlled via a scaling 
parameter. Weakly informative prior distributions were set for the overall Dirichlet 
distribution and study-to-study heterogeneity scaling parameter. Prior distributions 
summarize uncertainty about model parameters before examining the data.  
In this setup, the time-line up to last follow-up was partitioned into one-month time 
intervals. In particular, the follow-up time for OS was 33 months and thus we partitioned 
the time-line into 34 one-month grids as follows:   
[0,month 1), [month 1,month 2), … , [month 32,month 33), [month 34,∞). 
Similarly for PFS with follow-up time of 18 months, we partitioned the time-line into 
19 one-month grids.  
We defined the study-specific distribution, 𝐹1, as a DP with a scaling parameter 𝛼0, 
that governed the study-to-study heterogeneity, and a common base distribution, 𝐹0. To 
capture the uncertainty about this distribution, we let 𝐹0 itself be a draw from a DP with a 
base distribution measure 𝑆0 that governed the a priori distribution over the data, and a 
concentration parameter c that captured the amount of variability around the prior 𝑆0. This 
model is described as follows: 
𝐹1|𝛼0, 𝐹0~𝐷𝑃(𝛼0, 𝐹0) 
𝐹0|𝑐, 𝑆0~𝐷𝑃(𝑐, 𝑆0) 
 Let 𝑃0 and 𝑃1 correspondingly reflect the overall base probability and the study-
specific probability of an event occurring in each grid on the time-line.  Using the fact that 
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the Dirichlet distribution serves as an approximation to DP, these discrete time event 
probabilities follow 𝐺 −dimensional Dirichlet distributions described as follows:  
 𝑃0(grid 1), … , 𝑃0(grid 𝐺)~𝐷𝑖𝑟𝑖𝑐h𝑙𝑒𝑡 (𝑐[𝑆0(grid 1), … , 𝑆0(grid 𝐺)]) 
𝑃1(grid 1), … , 𝑃1(grid 𝐺)~𝐷𝑖𝑟𝑖𝑐h𝑙𝑒𝑡 (𝛼0(𝑃0(𝑔𝑟𝑖𝑑 1),… , 𝑃0(grid 𝐺)) 
By the multinomial-Dirichlet conjugacy, event and right-censored times then follow 
a multinomial distribution. The observed event times, 𝑧𝑖, have a support on the time-line 
up to 1 month after last follow-up. The censored times, 𝑡𝑘, still have a support on the same 
time-line, but they were sampled over the grids on the time line until the time of censoring 
with the grids after that collapsed into a single tail category: 
𝑧𝑖~Multinomial (𝑃1(grid 1), … , 𝑃1(grid 𝐺))   ∀ 𝑖 ∈ {1,… , 𝐼} , 
𝑡𝑘~Multinomial (𝑃1(grid 1), … , 𝑃1(grid 𝑟 − 1), ∑ 𝑃1(grid 𝑚)
𝐺
𝑚=𝑟 )   ∀ 𝑘 ∈
{1,… , 𝐾} , 
where I and K are the total number of events and censored observations correspondingly, 
and 𝑟 is the censoring time. 
Events that occurred in the tail of the distribution (after last follow-up time) were 
then modeled through a truncated Weibull survival model. The parametric nature of the 
Weibull model is well-suited to making inferences about the survival curve after the last 
follow-up time. The Weibull model was constructed by modeling survival times as random 
variables from a Weibull distribution within a Bayesian framework. The model had support 
on the whole time line beginning after the last follow-up time. 
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We used Markov chain Monte Carlo with Gibbs sampling to estimate the posterior 
distributions of 𝐹0 and 𝐹1 and the shape and scale parameters of the Weibull model in R 
through JAGS [45-47]. 
Model validation, sensitivity to survival function prior, and sensitivity to 
heterogeneity parameters are described and reported in Table 10, Figure 18, and Table 11, 
respectively. Samples from the posterior distribution were generated via Markov chain 
Monte Carlo (MCMC) implemented in JAGS and called via the rjags package in R [45-
47]. Posterior distributions summarize uncertainty about the model after examining the 
data. Five MCMC chains were used with the first 10,000 iterations of each discarded while 
the Markov chain stabilized. Posterior inference was based on 100,000 iterations from each 
of the chains, thinned at a lag of 50. 
For constructing patient trajectories in the pembrolizumab and chemotherapy arms, 
quantities of interest were posterior probabilities of death and progression within particular 
one-month time intervals up to the last follow-up, and posterior probabilities of death and 
progression on the continuous truncated time-line after the last follow-up time. Notably, 
the probability that a progression event occurred in a particular time interval was taken as 
the difference between the corresponding PFS and OS probabilities. Pembrolizumab and 
chemotherapy were compared based on 10,000 OS and progression times for each of the 
10,000 draws from the posterior distributions of probabilities. 
4.2.3 Disease model 
Cost-effectiveness of pembrolizumab relative to chemotherapy was assessed using 
simulated patient trajectories in the pembrolizumab and chemotherapy arms over a full 
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lifetime horizon (with one-month increments up to last follow-up and continuous time-line 
after last follow-up). Patients could transition from stable disease to one transition state, 
(1) progressive disease, and three absorbing states, (2) death, (3) discontinuation due to 
treatment-related adverse events, or (4) discontinuation upon progression. Probabilities for 
treatment discontinuation due to adverse events and probabilities for continuation after 
progression were obtained from Reck et al [20, 133]. In particular, patients in the model 
discontinued treatment due to adverse events with probability 13.6% in the pembrolizumab 
group, and 10.7% in the chemotherapy group. Upon progression, 44% of patients in the 
pembrolizumab group, and 54% of patients in the chemotherapy group underwent second-
line treatment. From a progressive disease state, patients could transition to absorbing 
states, (1) death or (2) treatment discontinuation. We assumed post-progression therapy 
discontinuation occurred after a median of 4 cycles for the pembrolizumab arm, and a 
median of 5 cycles for the chemotherapy arm. The state-transition diagram in Figure 13 
illustrates how patients flowed through the model. 
 
Figure 13: Patients flow 
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4.2.4 Dependency model 
Our analysis explored several levels of dependency between each simulated patient’s 
hypothetical disease trajectories in the pembrolizumab and chemotherapy arms, as well as 
between their progression and OS times. Intuitively, we might expect that a patient with 
longer time to progression would also have a longer survival time, and a patient with 
extended survival on pembrolizumab might also have a longer than typical survival time 
had they instead been treated with chemotherapy. The dependency model controlled the 
extent to which these event times were positively associated. Dependencies between each 
simulated patient’s four associated event times (progression and death for each of 
pembrolizumab and chemotherapy) were modeled via a Gaussian copula. 
We used a multivariate normal distribution to model the dependency between the 
pembrolizumab and chemotherapy arms and the dependency between progression and 
overall survival. We first generated four variables from a multivariate standard normal 













1 𝑝1 𝑝2 𝑝1𝑝2
𝑝1 1 𝑝1𝑝2 𝑝2
𝑝2 𝑝1𝑝2 1 𝑝1
𝑝1𝑝2 𝑝2 𝑝1 1
]), 
where 𝑝1 is the correlation between the pembrolizumab and chemotherapy arms, 𝑝2 
is the correlation between overall survival and progression, 𝑂𝑆𝐶 , 𝑂𝑆𝑃, 𝑃𝑟𝑜𝑔𝐶 and 𝑃𝑟𝑜𝑔𝑃 
indicate death time for chemotherapy and pembrolizumab, and progression time for 
chemotherapy and pembrolizumab respectively. The death and progression times for 
 66 
chemotherapy and pembrolizumab were then recovered by finding the bin (from the DP 
model) or the time point (from the Weibull tail) corresponding to Φ(𝑧), where Φ is the 





















Two scenarios, no and moderate dependency between hypothetical outcomes, are 
reported in the chapter. A high dependency scenario is described and reported in Appendix 
C.2. 
4.2.5 Cost Data 
Cost data for pembrolizumab and chemotherapy were based on UK and US costs of 
several aspects of treatment, care, and testing [141, 142]. The model included one-off costs 
for (1) PD-L1 testing, (2) enrolling under pembrolizumab therapy, (3) treatment initiation, 
resources upon progression specific to either (4) next line of treatment or (5) no further 
anti-cancer treatment, and (6) terminal care. Only those patients who entered the death state 
accumulated costs for end-of-life care. The model included weekly costs for resource use 
specific to (1) stable disease and (2) progressive disease. Treatment costs included all drugs 
used in first and second lines of therapy, (1) pembrolizumab (per 3-week cycle), (2) 
nivolumab (per 2-week cycle), and four platinum-based chemotherapy regimens per 3-
week cycles: (3) carboplatin plus pemetrexed (CARB+PEM), (4) carboplatin plus 
paclitaxel (CARB+PAC), (5) cisplatin plus gemcitabine (CIS+GEM), and (6) pemetrexed 
maintenance (PEM Maint). Patients in the chemotherapy arm received one of four first-
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line treatments, as reported in Reck et al [20, 133]. 30.7% received CARB+PEM followed 
by PEM maintenance, 37.3% CARB+PEM with no maintenance, 20.7% CIS+GEM, and 
11.3% CARB+PAC. Patients in the pembrolizumab arm received pembrolizumab as first-
line treatment.  Patients in the chemotherapy arm who received a post-progression 
treatment received either (1) pembrolizumab (88%), or (2) nivolumab (12%).  Assignment 
of post-progression treatments for the pembrolizumab arm was taken as equivalent to first-
line chemotherapy arm. All costs were converted to approximate 2018 US dollars, and can 
be found in Table 7.  
Toxicity managements costs[143-146] (Table 8) were included for several of the 
most common treatment-related and immune-mediated adverse effects. Hospitalization 
rates were obtained from Reck et al [20]. Adverse effects that were included were nausea, 
anemia, fatigue, diarrhea, neutropenia, vomiting, stomatitis, increased blood creatinine 
level, decreased platelet count, thrombocytopenia, decreased white-cell count, 
hypothyroidism, hyperthyroidism, and pneumonitis. 
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Table 7: UK and US costs of treatments, resources and tests for comparison of 
platinum doublet chemotherapy to pembrolizumab as first-line therapy for 
advanced NSCLC. All costs are in 2018 US dollars. Dosage for pembrolizumab is 
200 mg every 3 weeks and for nivolumab 240 mg every 2 weeks. 





Pembrolizumab (with one infusion added) per 3-week cycle 7,558 8,760 
CARB+PEM (with one infusion added)* per 3-week cycle 2,451 6,180 
CARB+PAC (with one infusion added)* per 3-week cycle 1,322 638 
CIS+GEM (with two infusions added)* per 3-week cycle 1,294 845 
PEM MAINT (with one infusion added)* per 3-week cycle 2,226 5,983 
Nivolumab per 2-week cycle 3,896 5,926 
PD-L1 single test one-time 57 60 
Total PD-L1 costs for enrolling under 
pembrolizumab therapy 
one-time 472 - 
Resource for treatment initiation one-time 1,023 1,000 
Resource use for progression-free health states weekly 93 419 
Resource upon progression to next line of 
treatment 
one-time 1,023 1,000 
Resource upon progression (no further anti-
cancer treatment) 
one-time 386 - 
Resource use for progressed disease health state weekly 98 - 
Resource for terminal care one-time 5,261 8,632 
*Assuming body surface area of 1.80 m², creatinine clearance of 80 mL/min/1.73 m², and £150 per 




Table 8: UK and US costs of adverse events for comparison of platinum doublet 
chemotherapy to pembrolizumab as first-line therapy for advanced NSCLC. All 
costs are in 2018 US dollars 
 
UK cost[143, 144] US cost[145, 146] 
 
  
 Grade <3 Grade ≥3 Grade <3 Grade ≥3 
Nausea 180 1,365 1,965 19,341 
Anemia 3,270 4,353 20,260 
Fatigue 2,902 16,185 
Diarrhea 555 1,365 3,265 16,510 
Neutropenia 225 5,321 17,181 
Vomiting 180 2,553 895 16,899 
Constipation - 2,591 20,949 
Stomatitis 144  1,695 18,151 
Increased blood creatinine level - 729 - - 
Decreased platelet count - 1,212 - - 
Thrombocytopenia - 1,212 6,325 22,698 
Decreased white-cell count -  - 
Dysgeusia - 3,700 23,187 
Hypothyroidism 610 2,255 20,428 
Hyperthyroidism 610 2,255 20,428 
Pneumonitis 2,214 9,941 21,929 
Infusion reaction - 4,782 22,860 
Severe skin reaction 143 940 15,709 
Colitis 1,266 6,079 20,208 
Pancreatitis - 15,943 32,918 
 
 
4.2.6 Effectiveness  
Patient-specific health utility values for each disease state (stable disease and disease 
progression) were taken according to distributions consistent with a UK-based study on 
health utilities for advanced NSCLC treated with immunotherapy or chemotherapy [147]. 
Utility values measure overall health and quality of life associated with each disease state. 
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Utility scores range from 1 (perfect utility) to 0 (death). Utility distributions are shown in 
Table 9.  
The British National Institute of Clinical Excellence (NICE) provides a framework 
for cost-effectiveness analysis. NICE recommends that end-of-life interventions that meet 
the end-of-life (EoL) threshold should be given perfect utility [141]. The NICE EoL 
threshold is constituted of (1) small patient population, (2) prognosis <24 months, and (3) 
life-extension >3 months  [148]. In the EoL adjusted analysis, a perfect utility was assigned 
to treatment with pembrolizumab if it extended life >3 months as compared to standard 
chemotherapy for the particular simulated patient.  
Quality-adjusted life-years (QALYs) were used to measure effectiveness. QALYs 
are a measure combining information on both quality of life and life expectancy. QALYs 
are calculated as a product of time spent in each state and the corresponding health utility, 
and they reflect a patient’s accumulated utility over time [149]. An analysis incorporating 
3% annual cost and utility discounting is described and reported in Appendix C.3. 
Table 9: Patient-specific utility distributions for advanced NSCLC treated with 
immunotherapy or chemotherapy 
State Adjusted utility 
Stable disease Uniform (0.563,0.743)  




Incremental cost-effectiveness ratios (ICERs) were calculated to evaluate cost-
effectiveness of pembrolizumab compared to standard chemotherapy. ICERs measure 
incremental cost per QALY gained. A treatment is commonly considered cost-effective if 
the ICER is below the GBP 30,000 threshold (approximately USD 42,048) or the USD 
100,000 threshold [149]. A sensitivity analysis basing the full cost-effectiveness analysis 
on a traditional Weibull model, instead of the combination DP-Weibull models, is 
presented in Appendix C.4. 
4.3 Results 
4.3.1 Data recovery 
Data recovery using graph capture and inverting KM equations was excellent. OS 
and PFS time-to-event data were extracted from published KM curves, numbers at risk, 
and censoring times from the KEYNOTE-024 study [20, 133]. The raw time-to-event data 
was recovered by the inverted KM equations, extending the techniques in Guyot et al [134]. 
Figure 14 and Figure 15 below display how the reconstructed KM curves compare to the 
original KM curves published in KEYNOTE-024. In the case of OS, the recovered KM 
curves for both chemotherapy and pembrolizumab almost completely overlap with the 
original KM curves confirming that the data was recovered well. In the case of PFS, the 
recovered overlap with the original curves with a slight difference present after month 12. 
The data was recovered well.  
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Figure 14. Reconstructed Kaplan-Meier curves for OS for the pembrolizumab and 
chemotherapy arms 
 




4.3.2 Survival model validation 
The DP-Weibull models validated well, accurately reproducing several OS and PFS 
summary statistics (Table 10). We validated the results of our survival model by comparing 
posterior summary statistics to summary statistics published in KEYNOTE-024 [20, 133]. 
We compared the median PFS and OS survival, the OS% at 12 and 24 months and the 
PFS% at 6 months for both arms. Table 10 below compares the reported statistics from the 
study to the ones recovered by the model. The model estimates were very close to the 
reported statistics. Additionally, Figure 16 and Figure 17 present the model fit for OS and 
PFS in both arms.  
Table 10: Comparison of reconstructed summary statistics to summary statistics 
published in KEYNOTE-024 [20, 133] – median OS and PFS, PFS% at 6 months, 
and OS% at 12 and 24 months for the pembrolizumab and chemotherapy arms 
 Reck et al. Model 
Median PFS survival for pembrolizumab (months) 10.3 10 
Median PFS survival for chemotherapy (months) 6 6 
Median OS survival for pembrolizumab (months) 30 30 
Median OS survival for chemotherapy (months) 14.2 15 
OS % at 12 months (pembrolizumab) 70.3% 71.1% 
OS% at 12 months (chemotherapy) 54.8% 54.9% 
OS % at 24 months (pembrolizumab) 51.5% 51.8% 
OS% at 24 months (chemotherapy) 34.5% 36.6% 
PFS % at 6 months (pembrolizumab) 62.1% 62.9% 
PFS% at 6 months (chemotherapy) 50.3% 49.9% 
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Figure 16. Reconstructed and fitted survival curves for OS for the pembrolizumab 




Figure 17. Reconstructed and fitted survival curves for PFS for the pembrolizumab 
and chemotherapy arms 
4.3.3 Survival prior distribution sensitivity analysis  
We explored the effect of the prior on the results by allowing the prior survival 
functions for both pembrolizumab and chemotherapy to vary anywhere between 0 and 1 
almost everywhere across the positive axis. Figure 18 shows the spread of the prior. In the 
case of OS in the pembrolizumab arm, the prior survival function was allowed to vary 
anywhere from 0.63 to 1 at month 1 with a mean at 0.97, from 0.27 to 1 at month 2, and 
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anywhere from 0 to 1 for the following months. Similarly, in the case of PFS in the 
pembrolizumab arm, the prior was allowed to vary from 0.52 to 1 at month 1, from 0.06 to 
1 at month 2, and from 0 to 1 the following months. Finally, for the chemotherapy arm, the 
prior for OS was spread between 0.42 and 1 at month 1 followed by a spread of 0 to 1 for 
the months afterwards, and for PFS it was allowed to vary from 0.18 to 1 at month 1 and 
then from 0 to 1 for the following months. The median OS and PFS times were 30 months 
(95% CrI 20-45) and 10 months (95% CrI 7-18) in the pembrolizumab arm, and 15 months 
(95% CrI 11-21) and 6 months (95% CrI 5-7) in the chemotherapy arm. The analysis 
showed that variations in priors within a sensible range had a limited qualitative effect on 
the outcome. 
 
Figure 18. Prior survival function and corresponding 95% CI on the spread of the 
prior for OS (top left) and PFS (top right) in the pembrolizumab arm, and for OS 
(bottom left) and PFS (bottom right) in the chemotherapy arm. 
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4.3.4 Heterogeneity sensitivity analysis  
 We explored the effect of variable levels of study-to-study heterogeneity on the 
results. As previously discussed, the model is described as follows: 
𝐹1|𝛼0, 𝐹0~𝐷𝑃(𝛼0, 𝐹0) 
𝐹0|𝑐, 𝑆0~𝐷𝑃(𝑐, 𝑆0) 
where the scaling parameter 𝛼0 governs the study-to-study heterogeneity. The 
heterogeneity parameter was allowed to vary anywhere from 1 (introducing high level of 
heterogeneity) to 1,000 (almost no heterogeneity). We used the 𝐼2 statistic to measure the 
magnitude of the between-study heterogeneity, where 𝐼2 ranged from 0 (low) to 1 (high). 
The 𝐼2 metric was based on variability of the median overall and progression-free survival 
time in the pembrolizumab and chemotherapy arms. When the initial heterogeneity was set 
to 1, the resulting 𝐼2 was modestly high. For 𝛼0 = 10, 𝐼
2 was modest to high, and for  𝛼0 ≥
100, 𝐼2 was low to modest. The results are shown in Table 11 below. We evaluated the 
cost-effectiveness of pembrolizumab in the case of high level of between-study 
heterogeneity, specifically when 𝛼0 = 1.  While there was a significant variability present 
within the overall survival distribution, the study-specific survival distribution exhibited 
little to almost no change. This behavior shows a limitation of our analysis that stems from 
the absence of multiple studies. Since the model was based on a single study, the analysis 
showed that introducing study-to-study heterogeneity had little qualitative effect on the 
results (see Table 21 in Appendix C.1). 
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Table 11: I^2 values for different levels of study-to-study heterogeneity across OS 
and PFS for the pembrolizumab and chemotherapy arms. I^2 metric based on the 
variability of the median OS and PFS for each arm 
 𝐼2 
 Pembrolizumab Chemotherapy 
𝛼0 OS PFS OS PFS 
1 0.57 0.14 0.72 0.76 
10 0.36 0.1 0.53 0.61 
100 0.05 0.22 0.09 0.32 
1000 0.03 0.02 0.06 0.01 
     
4.3.5 Cost-effectiveness 
For the no dependency among outcomes scenario, we modeled the two arms and their 
corresponding OS and PFS times as fully independent of each other. Patients who received 
chemotherapy gained a posterior mean of 1.11 QALYs (95% CrI 0.99-1.18). Patients who 
received pembrolizumab gained a posterior mean 1.93 QALYs (95% CrI 1.7-2.01) or EoL 
adjusted 3.06 QALYs (95% CrI 2.63-3.23). Posterior mean UK and US costs for the 
duration of therapy in the pembrolizumab arm were $99,000 (UK) and $132,000 (US), 
compared to $34,000 (UK) and $73,000 (US), respectively, for chemotherapy. These 
translated into posterior mean ICERs of $81,000 per QALY in the UK setting and $74,000 
per QALY in the US setting. With EoL adjustment, the respective UK and US posterior 
mean ICERs were $34,000 and $31,000 per QALY (Table 12 and Figure 19).  
The probability of pembrolizumab being cost-effective was <1% with respect to UK 
(USD 42,048) threshold without EoL adjustment, and 97.1% with EoL adjustment. The 
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probability that pembrolizumab was cost-effective with respect to US (USD 100,000) 
threshold was 97.2% without EoL adjustment and >99% with EoL adjustment (Figure 19). 
In the second scenario, we incorporated a moderate dependency between each 
simulated patient’s outcomes in the pembrolizumab and chemotherapy arms and between 
their associated OS and progression times by introducing a (latent) correlation of 0.5 
between the pembrolizumab and chemotherapy arms and a (latent) correlation of 0.8 
between progression and OS times via a Gaussian copula. In the chemotherapy arm, 
posterior mean QALYs gained decreased to 1.06, while mean treatment cost increased to 
$38,000 in the UK setting, and to $81,000 in the US setting. Mean cost in the 
pembrolizumab arm increased to $121,000 in the UK setting, and to $160,000 in the US 
setting. In the absence of EoL adjustment, mean QALYs gained by patients on 
pembrolizumab decreased to 1.80, leading to ICER per QALY of $115,000 for the UK and 
$110,000 for the US. With EoL adjustment, ICERs per QALY for the UK and US settings 
were $52,000 and $49,000, respectively (Table 12 and Figure 19). The probability of 
pembrolizumab being cost-effective in the UK was <1% with or without EoL adjustment. 
In the US setting, the probability that pembrolizumab was cost-effective was 25.32%, and 
99.8% with EoL adjustment (Table 12 and Figure 19).   
We explored a third, high dependence, scenario which incorporated a strong 
dependency between the arms and the progression and survival times. Results were 
qualitatively similar, with higher levels of dependency leading to higher ICERs, and can 
be found in Appendix C.2.  
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Figure 20 displays cost-effectiveness acceptability curves for pembrolizumab for the 
no and moderate dependency scenarios in a UK and US setting. In the UK setting, there is 
a 50% probability that pembrolizumab is cost-effective at a willingness-to-pay threshold 
of USD ≥51,000 per QALY in the scenario with EoL adjustment, and USD ≥111,000 per 
QALY without EoL adjustment. In the US setting, there is a 50% probability that 
pembrolizumab is cost-effective at a willingness-to-pay threshold of USD ≥48,500 per 
QALY in the scenario with EoL adjustment, and USD ≥106,500 per QALY without EoL 
adjustment. 
Additionally, a discounting factor was considered, but results were qualitatively 
similar with slightly higher ICER values (Appendix C.3). Finally, a relatively traditional 
survival model based on the Weibull distribution was considered, and the results were 
qualitatively similar to the DP-Weibull model in each of the no, moderate, and high 
dependency scenarios (Appendix C.4).   
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Table 12: Posterior mean (95% CrI) costs (2018 USD), QALYs and ICERs for 
comparison of platinum doublet chemotherapy versus pembrolizumab as first-line 
therapy for advanced NSCLC, under no dependency and moderate dependency 
between patients’ hypothetical outcomes 
 Chemotherapy Pembrolizumab 

































































































The success of immune checkpoint blockade has no parallel in recent medical 
oncology, however its costs are a matter of concern. Our current analysis indicates that 
pembrolizumab is likely to be cost-effective within the US but not in the UK. This 
difference across the Atlantic seems to stem from different willingness to pay thresholds 
(US USD 100,000, UK USD 42048), as the US and UK ICER values were close to each 
other in nearly all sensitivity and dependency analyses. Pembrolizumab was cost-effective 
in nearly all sub-analysis in US setting, whereas in the UK setting, evidence suggested it 
may be cost-effective only in the no dependency model, a fairly stringent assumption. 
We used the end of life adjustment [149]– a tool proposed and applied by NICE to 
assess therapies in challenging palliative settings – and the results became even more 
favored towards incorporation of pembrolizumab in the US. EoL adjustment also decreased 
the UK ICERs, but the values fell short of the current British willingness to pay threshold. 
It is noteworthy that ICER values were numerically similar between US and UK in all 
analyses, but the difference in thresholds (USD 100,000 in the US and USD 42000 in the 
UK) precluded a favorable opinion in UK setting. 
Moving beyond the US scenario, the enticing clinical results of pembrolizumab must 
be put into perspective against the backdrop of limited reimbursement supply, present even 
in the high-income world, as in the UK scenario. The conundrum between clinical efficacy 
and costs can reach dramatic proportions when a groundbreaking therapy emerges but its 
costs are prohibitive, which seems to be the case with first-line pembrolizumab for lung 
cancer in the middle and lower income countries. It is crucial to inform the general 
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population, patients, physicians, and paying sources about those limitations in order to best 
allocate scarce funds. 
A pragmatic approach to bring new and expensive drugs to clinics would be lowering 
their prices and some examples have shown this approach is feasible. For instance, 
nivolumab and pembrolizumab have been incorporated as second or third line therapy for 
lung cancer patients in the UK after NICE successfully negotiated lower costs and proposed 
more stringent patient selection [150]. Those treatments had original ICERs far above the 
British threshold, but became available to NHS patients after aggressive deals were struck 
with pharmaceutical companies. Even though these transactions were productive, this path 
may not be generalizable worldwide. Not all patients will be represented by a stakeholder 
with the bargaining power of the NHS, nor will there be alternative treatment to which 
patients can switch in the case of unproductive negotiations. 
Other proposals must also be explored. One alternative recently put forth is cost-
sharing between pharmaceutical companies and the reimbursement body, as in the Italian 
public health system by a manufacturer of another PD-1 antibody [151]. In that specific 
deal, initial costs would be defrayed by the reimbursement body and later drug-only costs 
by the pharmaceutical company. It is paramount to notice that the main cost still falls on 
the reimbursement body, as fewer patients will be at the tail of therapy and all non-drug 
costs are paid by the health care provider.  
Another approach for accepting more expensive drugs would be raising the 
willingness to pay bar in the specific scenarios of “end of life treatments”. This is a real 
alternative, already adopted by NHS for treating metastatic melanoma with ipilimumab, a 
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practice changing immunotherapy [152]. The current use of “end of life” adjustments 
supports the application of this tool in our present work. Those approaches are promising 
but may not suffice. A mixed option of discount, cost-sharing, end of life adjustment and 
multicriteria decision analysis [153] is more likely to be provide better access to high value 
therapies. 
A unique and very relevant feature of immunotherapy is the long-term survivorship 
brought by this type of treatment, that may not be captured by standard statistics used in 
cost-effectiveness analysis or studies with immature overall survival data [154]. The real - 
even though small - group of long term survivors may positively impact on survival 
outcomes, rendering the investment in the therapy still more appealing as the update of 
Keynote 024 has shown [133].  
Even though evidence suggests pembrolizumab may be considered cost-effective in 
the US, it is expected that immunotherapy costs will be a constant as newer therapies are 
set to be more expensive [155]. An example for the present day in the realms of lung cancer 
is the FDA approval of pembrolizumab combined with platinum doublet for first-line 
chemotherapy based on Keynote-021 [155]. Again, the clinical results are enticing, with 
subgroup analysis showing lasting tumor response in 80% of PD-L1 positive patients. 
However, it does not appear that immunotherapy-chemotherapy combination will become 
a cost-sustainable option even for this selected group at current costs of PD-1 therapy even 
in high income countries.  
As in most cost-effectiveness analyses, our results and conclusions were based upon 
adaptations from clinical trials to the real world and further limited by lack of 
 87 
comprehensive cost and survival data. In our model, patients received further treatment 
according to a distribution abstracted from the chemotherapy arm.  However, duration and 
outcomes on second-line treatment are not described in detail and there was a high rate of 
treatment cross over, adding uncertainty to the results [156]. Nevertheless, we used the 
most updated Keynote 024 results with mature overall survival [133].   
In spite of its limitations, our work can improve understanding of costs. Detailed 
costs of immune-related side-effects, both mild and severe, were retrieved and applied. 
Nivolumab, another expensive immunotherapy available as second or third line in the UK 
and US, entered the model as an option for further therapy. We ran analyses in two different 
scenarios: the mostly public-funded UK, and the mixed reimbursement US.  
A recent analysis by Huang et al. assessed cost effectiveness of pembrolizumab 
compared with platinum-based chemotherapy as first-line treatment in patients with 
metastatic NSCLC with PD-L1 expression ≥50% at $97,621 per QALY gained for the US 
[157]. That analysis was based on the preliminary data from Keynote 024 study, assumed 
a parametric distribution for the overall and progression-free survival and relied on lengthy 
extrapolation to model a 20-year time horizon. The study estimated the mean time in the 
PFS state for pembrolizumab and chemotherapy at 2.16 and 0.55 years respectively [157]. 
Our analysis on the other hand, estimated the mean time spent in the PFS state for 
pembrolizumab and chemotherapy at less than 10 and 6 months correspondingly, which is 
more consistent with the respective median PFS times of 10.3 and 6 months, as reported at 
Reck et al [20, 133]. Moreover, we included other PD-1 therapies and platinum-doublets 
as possible further therapies, which very likely increased the overall costs of therapies.  
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Cost-effectiveness studies aim to inform limitations of a given therapy and to allow 
a better decision-making process. Funders, pharmaceutical companies and, most 
importantly, patients and families must be actively involved in these decisions bearing in 




CHAPTER 5. BINOMIAL 𝒏 −PROBLEM 
5.1 Introduction 
Because of its applicability, the problem of estimating the success probability 𝑝 in a 
binomial Bin(𝑛, 𝑝) distribution when the number of trials 𝑛 is known is one of the most 
fundamental statistical problems finding place in introductory statistical textbooks. 
However, in some real-life situations, 𝑛 may not be known, and may be the parameter of 
interest. The binomial 𝑛 problem is a much less studied and a much more difficult problem.  
The most difficult cases involve simultaneous estimation of both 𝑛 and 𝑝, even when 
only a single observation might be available. The problem of estimating the parameters 𝑛 
and 𝑝 simultaneously has been first addressed in the literature by Whitaker [158], Fisher 
[159] and Haldane [160], who proposed the method of moments estimators (MME’s) and 
presented how the maximum likelihood estimates (MLE’s) may be computed. Fisher [159] 
didn’t take the problem seriously arguing that for sufficiently large number of observations 
𝑘, 𝑛 will be known. While this argument is correct, if 𝑝 is small, in practice 𝑘 will have to 
be unreasonably large for 𝑛 to be known with any degree of certainty.  
Classical procedures and their asymptotic properties were further critically assessed 
by Olkin et al [24], Carroll and Lombard [161], and Casella [162], who pointed out that 
the MME (introduced by Haldane [160]) and the MLE (introduced by Fisher [159]) 
estimators were highly sensitive to slight perturbations of the count data and hence 
unstable. This erratic behavior arises when the sample mean and sample variance of the 
observations are nearly equal. To overcome this lack of robustness, Olkin et al [24] 
 90 
proposed two stabilized versions of the MME and MLE estimators: jackknife-stabilized 
MLE:S, and ridge-stabilized MME:S. Both the MLE:S and MME:S estimators outperform 
the ordinary MLE and MME and are reasonably stable. Later, Carroll and Lombard [161] 
took a different approach to stabilizing the classical estimators. They suggested an 
alternative estimator MB(𝑎, 𝑏) by assuming a beta prior distribution for 𝑝 and maximizing 
an integrated likelihood. Casella [162] explored situations in which stabilized estimators 
are preferred over classical estimators. Further classic literature includes Blumenthal and 
Dahiya [163], Lindsay [164], Hall [165], Kuhne [166], and others. 
Recently, DasGupta and Rubin [167] proposed two new more efficient estimators. 
The first one is a new moment estimator that uses the sample maximum, the sample mean 
and the sample variance and is easy to motivate and compute. The second one is a bias 
correction of the sample maximum that performs very well and outperforms the Carroll-
Lombard estimate in many scenarios. The authors also derived the two estimators’ 
asymptotic properties. 
While most of the classical estimators of 𝑛 are based on MLE, MVUE or MME, 
several authors have considered the binomial 𝑛 problem from a Bayesian viewpoint. 
Draper and Guttman [23] proposed a Bayes point estimate assuming that the prior 
distribution of 𝑛 is discrete uniform on a set {1,2, … ,𝑁} with a prespecified upper bound 
𝑁. In the case when 𝑝 is known, the Bayes estimator coincides with the MLE solution of 
Feldman and Fox [168], and in the case when 𝑝 is unknown, 𝑝 is assumed to follow a beta 
prior distribution that is independent of 𝑛. Raftery [169] adopted a Bayes empirical Bayes 
approach within a hierarchical under the assumption that 𝑛 follows a Poisson distribution. 
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Kahn [170] demonstrated that the tails of the posterior distribution of 𝑛 are fully determined 
by the prior distribution of 𝑝, and do not depend on the data. Hamedani and Walter [171] 
investigated Bayes estimators based on a general prior distribution for 𝑛. Gunel and Chilko 
[172] proposed a Bayesian estimate under a continuous prior distribution for 𝑛.  More 
recently, Bayoud [173] proposed Bayes and empirical Bayes point estimates for 𝑛 under 
the assumption of a left-truncated Poisson prior distribution for 𝑛 and a beta prior 
distribution for 𝑝. Bayesian approaches seem to alleviate difficulties inherent to the 
classical approaches, but they do no appeal to asymptotic theory, consequently being for 
practical “small” problems.  
The simpler case of estimating the parameter 𝑛 when 𝑝 is known has been addressed 
by Feldman and Fox [168] who obtain estimates based on MLE, MVUE and MME and 
develop their asymptotic properties. Hunter and Griffiths [174], Sadooghi-Alvandi [175], 
Zou and Wan [176], Iliopoulos [177], Bayoud [173], and De and Zacks [178].  
The binomial 𝑛 problem when 𝑝 unknown continues to be a fundamentally difficult 
problem. As mentioned earlier the problem exhibits an inherent instability. Furthermore, 
DasGupta and Rubin [167] established that neither 𝑛 nor 𝑝 are unbiasedly estimable which 
imposes further difficulty obtaining good estimates. The most profound difficulty across 
estimators arises from their tendency to severely underestimate 𝑛, especially when either 
𝑛 is large, or 𝑝 is small. Furthermore, in the absence of replication, inference about 𝑛 is not 
possible. 
The problem that we address in this paper is estimating the parameter 𝑛 in a binomial 
distribution when 𝑝 is unknown for both cases of multiple observations and no replications. 
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5.2 𝒏 −estimators 
Given a random sample 𝑋1, … , 𝑋𝑘 of iid observations each drawn from a binomial 
distribution Bin(𝑛, 𝑝), where 𝑛, the total number of trials, and 𝑝, the success probability, 
are unknown, we consider the problem of estimating 𝑛. We assume that 𝑛 and 𝑝 are 
independent, 𝑛 ∈ {1,2, … } and 𝑝 ∈ (0,1). Define the sample mean, the sample variance 










 and 𝑥(𝑘) respectively. 
The 𝑛 binomial problem is a notoriously difficult one. The most common issue with 
estimators of 𝑛 is their instability. Both the MLE and MME estimators are highly sensitive 
to even slight perturbations of the data when the sample mean is nearly equal to or exceeds 
the sample variance. In order to avoid this issue, various stabilized estimators have been 
proposed, but a lot of them tend to underestimate 𝑛, especially when 𝑝 is small. Smaller 
variance occurs when 𝑝 is near 0 or 1. Variance is maximized at 𝑝 =
1
2
. Given a sample 
with a small variance, it’s hard to distinguish whether the sample comes from a population 
with small 𝑝 and large 𝑛, or large 𝑝 and small 𝑛. Most estimators tend to go for the latter 
and severely underestimate 𝑛, which poses a serious practical difficulty.  
DasGupta and Rubin [167] established the lack of unbiased estimates.  
Another difficulty is that, as noted by Student [179] and Olkin et al [24], there are 
certain ranges of the parameters 𝑛 and 𝑝 for which it is unclear whether the binomial or 
Poisson distribution is a better fit. If 𝑝 is small and 𝑛 is large, the Poisson distribution is a 
good approximation to the binomial distribution.  
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A more practical approach to the binomial 𝑛 problem is provided from a Bayesian 
standpoint. Analytical results might not be feasible, but numerical results are usually easy 
to obtain. Additionally, the Bayesian approach does not require any appeal to asymptotic 
distributional results. However, it exhibits an inherent challenge from a Bayesian 
perspective because n is discrete. That restriction leads to a limited choice of prior 
distributions. Furthermore, Jeffrey priors are not defined. Additionally, the posterior of 𝑛 
must be restricted to 𝑛 ≥ 𝑥(𝑘).  
Kahn [170] showed that for large 𝑛 the tail weight of the marginal posterior 
distribution of 𝑛 is totally determined by the choice of prior distribution on 𝑛 and 𝑝 rather 
than the data. In fact, the tail of this posterior is not asymptotically affected by the data. 
Finally, the Bayesian approaches pose an additional question on how one should 
specify the parameters of the prior distributions.  
Now, we present existing estimators of the sample size 𝑛 when 𝑝 is unknown.  
5.2.1 Estimators related to the sample maximum 
5.2.1.1 Sample maximum 
A trivial estimator of 𝑛 is 𝑥(𝑘). As 𝑘 → ∞, the maximum sample is a consistent 
estimator of 𝑛, but a biased one as it can severely underestimate 𝑛. In practice, 𝑘 will have 
to be unrealistically large before 𝑛 can be known with any degree of certainty. One can 
modify the estimator by adding a constant 𝑟. Feldman and Fox [168] showed that the 
estimator 𝑥(𝑘) + 𝑟 is still a consistent estimator of 𝑛 as 𝑛, 𝑘 → ∞ provided that 𝑘𝑝
𝑛𝑛𝑟−1 →
∞, but it is nevertheless still unreliable. 
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5.2.1.2 Bias correction of the sample maximum 
An attempt to improve the sample maximum estimator is to incorporate a bias 
correction. DasGupta and Rubin [167] introduced the following bias corrected estimator 
by obtaining a bound on the average bias of 𝑥(𝑘) averaged over 𝑝: 









−1 denotes the quantile function of the Beta(𝑟, 𝑠) distribution and ?̃? is some 
suitable (preliminary) estimate of 𝑛. 
5.2.2 Estimators related to MME 
5.2.2.1 MME 









While the MME estimators are consistent, they do not seem to be fully efficient 
according to Haldane [160]. The MME estimator is very unstable when 𝑠2 is close to ?̅?.  
Furthermore, produces negative estimates with positive probability. Despite its erratic 
behavior especially when 𝑛 is large and 𝑝 is small, the MME can still be a useful estimate.  
Binet [180] showed that if the MLE estimator exceeds one hundred, very little information 
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or efficiency is lost by using the MME estimator instead. Furthermore, the MME is simple 
to compute. 
5.2.2.2 Stabilized MME 
Olkin et al [24] proposed a stabilized version of the MME estimator. In the case when 
𝑠2 is close to ?̅? and the MME is not stable, the authors suggested perturbing the observed 
sample by a small constant 𝜖 > 0, so that the sample mean of the perturbed observations 










































where 𝑧𝑘 = 𝛷
−1(2−1/𝑘), and 𝛷 denotes the standard normal cumulative distribution 
function. 
5.2.2.3 A new moment estimate 
DasGupta and Rubin [167] introduced a new moment estimate, that incorporates 






The estimator is easy to compute. The authors state that a good choice for 𝛼 is 1.  
 96 
5.2.3 Estimators related to MLE 
5.2.3.1 MLE 
The maximum likelihood estimator, MLE, is defined as:  
?̂? = {
𝑥(𝑘), if    𝑑(𝑥(𝑘)) ≤ 0
∞, if    𝑠2 ≥ ?̅?
solution of 𝑑(𝑛) = 0, if    𝑑(𝑥(𝑘)) > 0 and  𝑠
2 < ?̅?  
 
where 𝑑(𝑛) = 𝑘 log (1 −
?̅?
𝑛







  with 𝑁𝑥 being the sample frequency of 
𝑥. The maximum likelihood equation 𝑑(𝑛) is presented by Fisher [159] and Haldane 
[160].Olkin et al [24] shows that the likelihood equation leads to a unique MLE estimator 
if 𝑑(𝑥(𝑘)) > 0. Similarly to the MME estimator, as 
?̅?
𝑠2
→ 1, the estimator become less 
stable and more sensitive to small changes in the success counts.  Furthermore, as 𝑛 → ∞, 
it is not necessarily true that 𝐿(𝑛) → ∞, where 𝐿(𝑛) is the likelihood function, thus causing 
instability issues. 
5.2.3.2 Stabilized MLE 
Olkin et al [24] robustified the MLE estimator through a jackknife procedure and 
arrived at the following stabilized MLE estimator that is either the ordinary MLE estimator 






 MLE,                                        if    
?̅?  
𝑠2










where 𝑥(𝑘−1) is the 𝑘 − 1 order statistic. 
5.2.3.3 Second stabilized MLE 
Casella [162] analyzed the stability of the MLE estimator by perturbing the log 
likelihood function in a systematic fashion. The author argues that the instability arises 
from the first term in the log likelihood function given below: 






+ 𝑘?̅? log 𝑝 + 𝑘(𝑛 − ?̅?) log(1 − 𝑝). 
The goal is to perturb the first term by replacing the log 𝑛! and log(𝑛 − 𝑥𝑖)! terms 
with the following approximation: 
log 𝑦! ≈ (1 − 𝛼)𝑦 log 𝑦 + 𝛼(𝑦 + 1) log(𝑦 + 1), 
for some 𝛼 ∈ (0,1). For 𝛼 near 
1
2
, the perturbed likelihood is very close to the original one. 
For a range of 𝛼 values near 
1
2
, the author examines the maximum likelihood estimators 
resulting from those slightly perturbed likelihood functions. Differentiating 𝑙(𝑛, 𝑝|𝑋, 𝑘) 






 𝑛(1−𝛼)𝑘(𝑛 + 1)𝛼𝑘 [


















The MLE of 𝑝 based on the perturbed likelihood is ?̂?𝛼 =
?̅?
?̂?𝛼
. Casella shows that for 
a fixed 𝛼, the perturbed likelihood has a unique finite root ?̂?𝛼. To obtain a point estimate 
















5.2.3.4 Likelihood weighed by beta prior for 𝒑 
Consider the conjugate Beta(𝛼, 𝛽) prior distribution on the parameter 𝑝. The 
justification behind the beta distribution is that it does not impose any severe limitations 
on the way the probability fluctuates, yet it is versatile. The marginal posterior distribution 




) 𝑝𝑥𝑖(1 − 𝑝)𝑛−𝑥𝑖
𝑘
𝑖=1






𝛣(𝛼 + ∑ 𝑥𝑖
𝑘











Carroll and Lombard [161] obtain an estimator by maximizing the marginal posterior 
as a function of 𝑛 ≥ 𝑥(𝑘) for some given 𝛼 and 𝛽. According to DasGupta and Rubin [167], 
it is the best available estimate of 𝑛. 
Skellam [181] discussed how to obtain satisfactory estimates of the parameters 𝛼 and 
𝛽 through the method of moments through the following relation: 
 99 
𝛼 =
𝑅1𝑅2 − (𝑛 − 1)𝑅1
(𝑛 − 1)𝑅1 − 𝑛𝑅2
 







. More efficient parameters can be obtained by directly 
maximizing the log likelihood instead. 
Carroll and Lombard [161] examine this problem when 𝛼 and 𝛽 are integers. Their 
estimator MB(𝛼 − 1, 𝛽 − 1) is obtained by maximizing the integrated likelihood as a 








(𝛼 + 𝛽 + 𝑘𝑛 − 1) (
𝛼 + 𝛽 + 𝑘𝑛 − 2





Notice that the likelihood is optimized over a continuous range of 𝑛.  
5.2.4 Bayesian approaches 
5.2.4.1 Beta prior for 𝒑, and discrete uniform prior for 𝒏 
Consider the Beta(𝛼, 𝛽) and Uniform(1, 𝑁) priors on 𝑝 and 𝑛 respectively (where 𝑁 
is some large preselected integer). These priors have been used by Draper and Guttman 
[23]. Under the assumption that 𝑛 and 𝑝 are independent a priori, and after integrating 𝑝 
out, the marginal posterior of 𝑛 becomes 
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𝑝(𝑛|𝑋) ∝
(𝑘𝑛 − ∑ 𝑥𝑖
𝑘
𝑖=1 + 𝛽 − 1)!






     for max
 
𝑥𝑖 ≤ 𝑛 ≤ 𝑁 
Draper and Guttman consider the modal value of the marginal posterior distribution 
as an estimate of 𝑛 under the absolute loss function. 
In the case when 𝛼 = 𝛽 = 1, 𝑝 follows an arguably noninformative uniform prior 
distribution. Under that assumption, the authors argue that the choice of the upper bound 
𝑁 does not affect the inferred value of 𝑛 as long as 𝑁 does not limit the upper tail. Kahn 
[170] notes that this is incorrect, since when 𝑁 increases, both the mean and the median of 
the posterior of 𝑛 get arbitrarily large.   
Prior information on 𝑝 can be very easily incorporated into the model by selecting 
the parameters 𝛼 and 𝛽 to match the most likely a priori value of 𝑝 and the “strength” of 
the prior belief. Prior information on 𝑛 is as easy to incorporate, thus the method is 
nonrestrictive.  
5.2.4.2 Uniform prior for 𝒑, and Poisson prior for 𝒏 
Assume that 𝑛 follows a Poisson(𝜇) prior distribution. The observations 𝑋𝑖’s then 
follow a Poisson distribution with mean 𝜆 = 𝜇𝑝, where 𝜆 and 𝑝 are assumed to be 
independent a priori. Raftery [169] adopts a hierarchical approach to the problem by 
specifying a standard vague prior for λ and a uniform prior for p (prior specified in terms 
of (𝜆, 𝑝) instead of (𝜇, 𝑝)) such that 
𝑝~Uniform(0,1)                                 
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.                                      
which leads to a posterior distribution of 𝑛, that is 
𝑝(𝑛|𝑥) ∝ {
(𝑘𝑛 − ∑ 𝑥𝑖
𝑘
𝑖=1 )!







}             (𝑛 ≥ 𝑥(𝑘) ) 
5.2.4.3 Beta prior for 𝒑, and Poisson prior for 𝒏 
Hamedani and Walter [171] investigate the case where 𝑝 follows a beta prior, while 
𝑛 follows a Poisson prior: 
𝑝~Beta(𝛼, 𝛽) 
𝑛~Poisson(𝜆). 






















𝑑𝑝 𝛣(𝛼, 𝛽)       𝑛 ≥ 𝑥(𝑘). 
The resulting estimator for 𝑛 does not have a simple closed form expression, though.  
5.2.4.4 Beta prior for 𝒑, and left truncated Poisson prior for 𝒏 
Since n is the number of trials, n has to be greater than or equal to 1. Bayoud [173] 
assumes that n follows a zero truncated Poisson distribution and investigate the model  
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𝑝~Beta(𝛼, 𝛽) 
𝑛~zero truncated Poisson(𝜆). 
The marginal posterior pdf of 𝑛 is then given by 





𝛤(𝑘?̅? + 𝛼)𝛤(𝑘𝑛 − 𝑘?̅? + 𝛽)












𝛤(𝑇𝑘 + 𝛼)𝛤(𝑘𝑛 − 𝑇𝑘 + 𝛽)

















𝛤(𝑘𝑛 − 𝑇𝑘 + 𝛽)










Bayoud [173] also discusses how to construct an empirical Bayes estimate for 𝑛 by 
obtaining MME values for the hyperparameters 𝛼, 𝛽 and 𝜆. 
5.2.4.5 Continuous prior for 𝒏 
Even though the number of trials 𝑛 is a discrete random variable, as an 
approximation, Gunel and Chilko [172] considered a continuous prior for 𝑛. The model is 
specified as follows: 
𝑝~Beta(𝛼, 𝛽) 
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𝑛~Gamma(𝛼 + 𝛽, 𝛿), 
where 𝑝 and 𝑛 are independent. The justification behind a continuous prior for 𝑛 stems 
from the approximated value of 𝑛, 𝑛 ≈ 𝜆 + 𝜆′, where 𝜆~Gamma(𝛼, 𝛿) and 
𝜆′~Gamma(𝛽, 𝛿). The estimator does not have a closed form and is evaluated using the 
Laguerre-Gauss quadrature.  
5.2.4.6 Improper prior for 𝒏 
Hamedani and Walter [171] investigate the effect of improper priors for both 𝑛 and 
𝑝 and show that improper priors lead to implausible results.  
5.3 A Beta-Binomial MLE Approach 
Let 𝑋1, … , 𝑋𝑘~Bin(𝑛, 𝑝), where 𝑛 and 𝑝 are assumed to be independent, and 𝑛 ∈
{1,2, … } and 𝑝 ∈ (0,1). Observe that the likelihood function of 𝑛 and 𝑝 given 𝑋1, … , 𝑋𝑘 is 
given by: 
L(𝑛, 𝑝|𝑥1, … , 𝑥𝑘) =∏(
𝑛
𝑥𝑖




The function has to be maximized with respect to 𝑝 and 𝑛 simultaneously, where the 
range for 𝑛 is restricted to 𝑛 ≥ max{𝑥(𝑘), 1}. Since the parameter 𝑝 is unknown, we let 𝑝 
fluctuate by viewing it as a random variable arising from the conjugate Beta(𝛼, 𝛽) prior 
distribution given by:  
𝑔(𝑝|𝛼, 𝛽) =




where 𝛣 is the usual beta function, 𝛼, 𝛽 > 0, and 𝑝 ∈ [0,1]. The beta distribution lets 𝑝 
take a variety of shapes between 0 and 1, and imposes no severe restrictions on the 
parameter. After integrating 𝑝 out, the modified likelihood becomes  










) 𝑝𝑥𝑖(1 − 𝑝)𝑛−𝑥𝑖
𝑘
𝑖=1



















A fundamental problem when using the Beta-Binomial distribution is the estimation 
of the parameters 𝛼 and 𝛽. In this setup, one additional parameter needs to be estimated, 
𝑛. One possible method is to use the method of moments through the following relation 







𝑛𝛼 + 𝛽 + 𝑛





(𝛼 + 𝛽) 
(𝑏2 + 3𝑛𝛽 + 2𝑛2 + 𝑛2𝛼2 + 𝛼(3𝑛2 + 𝛽(3𝑛 − 1)))
(𝛼 + 𝛽 + 1)(𝛼 + 𝛽 + 2)
 
Skellam [181] discussed how to obtain satisfactory estimates of the parameters 
through the first three moments of the distribution. While this approach is simple and 
computationally easy, it is not very efficient, and can lead to negative estimates.  
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A second more efficient, and our preferred, method of obtaining satisfactory 
estimates of the parameters 𝛼, 𝛽 and 𝑛 is to use maximum likelihood approach. The log 
likelihood function 
𝑙(𝑛, 𝛼, 𝛽) = 










− log Β(𝛼, 𝛽) 
is directly maximized with respect to integer values of 𝑛 ≥ max{𝑥(𝑘), 1}, and continuous 
values of 𝛼, 𝛽 ≥ 0. Thus, the estimates of 𝑛, 𝛼, 𝛽 are given by 
(?̂?, ?̂?, ?̂?) = arg max
𝑛≥max{𝑥(𝑘),1},𝑛∈ℤ,𝛼>0,𝛽>0
𝑙(𝑛, 𝛼, 𝛽). 
Optimizing the likelihood function with respect to all three parameters, allows the 
inference based on the data of not only 𝑛, but 𝛼 and 𝛽 as well. Furthermore, Carroll and 
Lombard [161] state that if 𝛼, 𝛽 ≥ 0, then the likelihood is maximized at some finite 𝑛. 
 As mentioned earlier, the beta distribution is a flexible distribution with density that 
can take on a number of shapes. When both 𝛼, 𝛽 < 1, the density is U-shaped and more 
sparse. If 𝛼 < 1 or 𝛽 < 1, the distribution is reverse J- and J-shaped respectively. When 
𝛼 = 𝛽 = 1, the density is flat (uniform) on the unit interval. Finally, as 𝛼, 𝛽 increase, the 
density “tightens” around its mean and resembles a spike. 
 To overcome instability and make the ?̂?, ?̂?, and ?̂? estimators more robust, we 
restricted the parameter space of 𝛼 and 𝛽 to (0,1000), where the upper bound was 
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somewhat arbitrarily chosen. The imposed restriction is still flexible enough to 
accommodate all of the above mentioned different shapes of the beta distribution. The 
lower and upper bounds of 𝛼 and 𝛽 permit the mean (variance) of 𝑝 to vary anywhere from 
0 to 1 (0 to 0.25), where 𝑝 is estimated as 
𝛼
𝛼+𝛽
. Limiting the upper bound for 𝛼 and 𝛽 leads 
to a more cautious inference about n. The final form of our estimator is as follows: 
(?̂?, ?̂?, ?̂?) = arg max
𝑛≥max{𝑥(𝑘),1},𝑛∈ℤ,𝛼,𝛽∈(0,1000)
𝑙(𝑛, 𝛼, 𝛽). 
 We optimized the log likelihood function using a grid search over integer values 
for 𝑛, and a limited memory modification of the BFGS quasi-Newton method proposed by 
Byrd et al [182]. The BFGS is a quasi-Newton algorithm that was published simultaneously 
by Broyden, Fletcher, Goldfarb and Shanno Broyden, Fletcher, Goldfarb and Shanno in 
1970 [183-186]. We used the gridSearch function within the NMOF package in R [187, 
188], and the optim function within the stats package in R [45]. 
Similar approach has been proposed previously by Carroll and Lombard [161] and 
Blumenthal and Dahiya [163]. Carroll and Lombard [161] suggested an estimator by 
maximizing the integrated likelihood as a function of 𝑛 ≥ 𝑥(𝑘);  𝛼 and 𝛽 were set at some 
pre-selected integer values.  Blumenthal and Dahiya [163] maximized the product 
∏ 𝑃(𝑥𝑖|𝑛, 𝑝)
𝑘
𝑖=1 𝑃(𝑝|𝛼, 𝛽) directly over 𝑛 and 𝑝 without integrating 𝑝 out. They do not 




5.4 Performance Investigation and Applications 
5.4.1 Illustrative Example 
Consider the random sample {16,18,22,25,27} generated from a binomial 
distribution with 𝑛 = 75 and 𝑝 = 0.32 investigated by Olkin et al [24]. The MME and 
MLE estimates are 102 and 99 respectively. Suppose that the 27 in the sample was 
misrecorded, and the correct value was 28. The MME and MLE estimates then become 
195 and 190, which shows their lack of robustness. This is an example of an unstable case 
since the sample mean and sample variance are nearly equal. The proposed estimator based 
on Beta-Binomial MLE approach is 70 before correcting the sample, and 85 after. 
5.4.2 Comparative performance 
In this section, we compare the performance of five different 𝑛 −estimators for 
different combinations of (𝑘, 𝑛, 𝑝). The five estimators include the stabilized method of 
moments and stabilized maximum likelihood estimators as presented by Olkin et al Olkin 
et al [24] (MME:S and MLE:S), the Carroll and Lombard [161] estimators (MB(0,0) and 
MB(1,1)), and the proposed estimator ?̂?.  
 First, we present results for eight particularly difficult cases selected by Olkin et al 
[24]. We also present results for each perturbed sample obtained by adding one to the 
sample maximum. The results are shown in Table 13. The proposed estimator is reasonably 
stable when subjected to perturbations. The estimator ?̂? was closer to the true value of 𝑛 
than the other six estimators in one case. The MME and MLE estimators are highly unstable 
though. If we disregard those two unstable estimators, ?̂? was closer/equally close to the 
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true value of 𝑛 compared to the other four estimators in two cases. Finally, ?̂? outperformed 
both MB(0,0) and MB(1,1) in three cases. It performed similarly well in another three 
cases, but exhibited higher instability. Sample #6 is of particular interest since it is an 
unstable case with large 𝑝. The MLE:S dominates all estimators followed by the ?̂? 
estimator. Finally, if we restrict our attention to sample 8, which is an example of unstable 
case with small 𝑝, we observe that MME:S is the best estimator (excluding MME and MLE 
due to instability), and the ?̂? estimator is next. 
Table 13: n- estimators for selected samples and perturbed samples. 
Sample 𝑛 𝑝 𝑘 MME MLE MME:S MLE:S MB(0,0) MB(1,1) ?̂? 
















































































































Note: The exact samples can be found in Table 2 of Olkin et al [24] 
P: perturbed sample 
 
Next, we conducted a simulation study to compare the performance of the five 
estimators. Following the same design found in the study by Olkin et al [24], we generated 
values of 𝑘, 𝑛 and p from uniform distributions on {3, … ,22}, {1, … ,100} and (0,1) 
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respectively. We generated 100,000 random binomial samples, and computed the five 
estimators for each sample.  
The performance of the estimators was evaluated based on three criteria. The first 






]. Several authors including Olkin et al [24], Carroll and Lombard [161], and 
Casella [162] have suggested that the scaled squared error is an appropriate and natural 
loss function for this problem. For easier interpretation, we reported relative mean square 
error efficiency instead. A relative mean square error efficiency of an estimator ?̂? relative 
to a benchmark estimator ?̅? is the ratio of the relative mean square error of ?̅? to the relative 
mean square error of ?̂?. The second criterion is the bias, defined as E[
?̂?
𝑛
− 1] similarly to 
the study of Blumenthal and Dahiya [163]. Lastly, we computed the number of times each 
estimator “won” (was closest to the true value of 𝑛). Ties were counted as wins.  
Finally, each sample was categorized as either stable or unstable. We used the 








The relative mean square errors efficiency, bias and number of wins for both the 
stable and unstable cases are showed in Table 14.  
Overall, the ?̂? estimator performed slightly better than the other four estimators with 
an overall efficiency gain of about 4% and 1% over MME:S and MB(1,1) respectively. In 
terms of proximity to the true 𝑛, the ?̂? estimator won/tied in 42% of the cases, while the 
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MB(1,1) and MME:S both won/tied in about 50% of the cases. The MLE:S estimator 
performed the worst in terms of efficiency and bias, and second worst behind MB(0,0) in 
terms of number of wins. The MB(1,1) outperformed MB(0,0) across all three measures of 
error. 
However, in stable cases, which occurred 69.4% of the time, the ?̂? estimator 
performed slightly worse than or equally well at best compared to the other estimators with 
an overall efficiency loss of 1% over MME:S. MB(1,1) had an overall efficiency gain of 
1% over MME:S and won/tied in 63% of the cases. The MB(1,1) performed the best across 
all three measures of error. MB(1,1) again outperformed MB(0,0) across all three measures 
of error. 
In unstable cases (30.6% of all cases), the  ?̂? estimator dominated all other estimators, 
and showed an 8% overall efficiency gain over MME:S, and about 4% over both MB(0,0) 
and MB(1,1). In terms of bias and number of wins, MME:S performed the best followed 
by the proposed ?̂? estimator. This time, MB(1,1) performed similarly to or worse than 
MB(0,0) across all three measures of error. The ?̂? estimator outperformed MLE:S, MB(0,0) 






Table 14: Comparison of the n-estimators. 
 Cases  MME:S MLE:S MB(0,0) MB(1,1) ?̂?  
All cases 10000 Efficiency 1.00 0.93 1.02 1.03 1.04 
Bias -0.186 -0.304 -0.223 -0.23 -0.218 




Efficiency 1.00 0.99 0.99 1.01 0.99 
Bias -0.172 -0.179 -0.185 -0.165 -0.187 




Efficiency 1.00 0.9 1.05 1.05 1.09 
Bias -0.217 -0.583 -0.309 -0.375 -0.286 
Wins 47% 19% 19% 19% 41% 
 
We investigated the performance of the estimators further by splitting the parameter 
range for 𝑝 into several overlapping categories following Olkin et al [24]. For stable cases, 
MB(1,1) achieved highest efficiency across values for 𝑝 ∈ (0.2,1), which can be explained 
by the tendency of the MB(0,0) and MB(1,1) estimators to downweigh the possibility that 
𝑝 is near zero. For “small” values of 𝑝, (0 < 𝑝 < √2 − 1), the MME:S achieved the best 
performance.  
In the special unstable case with “small 𝑝” (0 < 𝑝 < √2 − 1) the proposed ?̂? 
estimator was superior to the other estimators, followed by MME:S. For bigger values of 
𝑝 the MB(1,1) performed better than all other estimators. 
5.5 𝒏 −estimator when 𝒌 = 𝟏 with Applications in Contingency Tables 
5.5.1 Background 
In the absence of replications, inference about 𝑛 is not possible. And yet, the need 
for an 𝑛 −estimator, even when only a single observation is available, arises in certain 
 112 
situations, particularly in analyzing partially reported contingency tables when the interest 
lies in inference about unobserved cell counts.  
Consider a simple 2 × 2 contingency table design, where the columns are counts of 
subjects who have a particular disease of interest and those who do not, and the rows are 
counts of those subjects who tested positive and negative for the disease. A standard 
assumption is that the disease and no disease groups are independent. Suppose that the test 
found agreement in 𝐴 subjects for being positive (true positives), and in 𝐷 subjects for 
being negative (true negatives). Let 𝐵 represent the number of subjects who do not have 
the disease and tested positive (false positives), and 𝐶 the number of subjects who have the 
disease and tested negative (false negatives). The contingency table design for evaluating 
the performance of a test can be represented as Table 15.  
Table 15: Contingency design table 
  Disease No disease  Total 
Test positive 𝐴 𝐵 𝐴 + 𝐵 
Test negative 𝐶 𝐷 𝐶 + 𝐷 
 Total A + 𝐶 𝐵 + 𝐷 𝐴 + 𝐵 + 𝐶 + 𝐷 
 
Some studies report only the number of true positives and true negatives, that is cell 
counts 𝐴 and 𝐷. When 𝐵 and 𝐶 are not reported, the total number of subjects who have the 
disease 𝐴 + 𝐶 and the total number of subjects who do not have the disease 𝐵 + 𝐷 are 
unknown. This is problematic since in order to determine a test’s performance, a key 
quantity of interest is the sensitivity and specificity of the test. Sensitivity is the ability of 
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a test to identify correctly those who have the disease, and specificity is the ability to 
identify correctly those who do not have the disease. The sensitivity (true positive rate) and 









where * refers to counts that are not reported. 
With the increase in knowledge and technology in the medical field in recent years, 
an increasing number of diagnostic tests for different diseases has become available. 
Diagnostics tests should be used based on their validity, and not availability. Validity of a 
test can be characterized by its sensitivity and specificity.  
This section addresses the problem of inference on the sensitivity and specificity for 
a test in a missing data context when only the true positives 𝐴 and true negatives 𝐷 are 
reported. Equivalently, the problem can be translated in the context of the binomial 𝑛 
problem with 𝑘 = 1 replications. The problem now is to estimate column totals  A + C∗ 
and 𝐵∗ + 𝐷 conditional on the observed values of some cell counts (true positives 𝐴 and 
true negatives 𝐷). We propose a Bayesian model to recover the contingency table by 




5.5.2 Bayesian Model 
Assume that Table 15 is partially observed, that is 𝐴 and 𝐷 are known, while 𝐵 and 
𝐶 are unknown. Since the disease and no disease populations are independent from one 
another, we can treat each of 𝐴 and 𝐷 as a realization of an independent binomial 
distribution as follows: 
𝐴~Binomial(𝑛1, 𝑝1) 
𝐷~Binomial(𝑛2, 𝑝2), 
where 𝑛1 = 𝐴 + 𝐶
∗, 𝑛2 = 𝐵
∗ + 𝐷, and the probabilities 𝑝1 and 𝑝2 of testing positive 
(negative) in the presence (absence) of the disease are unknown. A natural restriction is 
that 𝑛1 ≥ 𝐴 and 𝑛2 ≥ 𝐷. 
We propose a Bayesian approach to the problem. We assume that the sample sizes 
𝑛1 and 𝑛2 follow a Poisson distribution with parameters 𝜆1 and 𝜆2 respectively. The 
Poisson distribution accommodates the discrete nature of the parameters. Additionally, we 
let the probabilities 𝑝1 and 𝑝2 each be a draw from a uniform distribution 
Since sensitivity and specificity are both usually in the interval [0.5,1], we let 𝑝1 be 
a draw from a Uniform(0.5,1) distribution.  
In practice, for any test, there is a tradeoff between sensitivity and specificity. Due 
to a minimum error bound, as sensitivity increases, specificity decreases, and vice versa. 
Therefore, to quantify and incorporate this tradeoff into our model, we let sensitivity and 
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specificity together (𝑝1 + 𝑝2) vary from 1.4 to 1.8. Therefore, we assume that 𝑝2 follows a 
Uniform(1.4 − 𝑝1, 1.8 − 𝑝1) distribution. 
Finally, 𝜆1 and 𝜆2 are each selected based on prior knowledge about 𝐴 + 𝐶
∗ and 
𝐵∗ + 𝐷 respectively. The [0.5,1] range for sensitivity and specificity limits the range for 
𝑛1 and 𝑛2 to [𝐴, 2𝐴] and [𝐷, 2𝐷] respectively. Using this restriction, if there is no prior 








The model has the following form: 
𝐴|𝑛1, 𝑝1~Binom(𝑛1, 𝑝1) 
𝑝1~Uniform(0.5,1) 
𝑛1|𝜆1~Poi(𝜆1) 
𝐷|𝑛2, 𝑝2~Binom(𝑛2, 𝑝2) 
𝑝2|𝑝1~Uniform(1.4 − 𝑝1, 1.8 − 𝑝1) 
𝑛2|𝜆2~Poi(𝜆2) 
We generated samples from the posterior distribution using Markov chain Monte 
Carlo (MCMC) algorithm implemented in JAGS via the rjags package in R. We used 1 
chain with the first 10,000 iterations discarded while the Markov chain stabilized. 
Assuming quadratic loss function, posterior inference was based on posterior means 
generated from 50,000 samples thinned at a lag of 50.  
5.5.3 Example 
In this section, we demonstrate how our methodology can be used to recover 
contingency tables and to estimate sensitivity and specificity. Consider the following fully 
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observed contingency table from a study by Tubman et al [189] . The study investigated 
the performance of different screening tests for detecting congenital heart disease early in 
the life of children with Down’s syndrome. Table 16 shows the diagnostic ability of a 
combination of clinical examination, chest radiography and electrocardiography: 
Table 16: Original contingency table reported by Tubman et al [183] 
  Disease No disease 
Test positive 24 4 
Test negative 10 43 
 
Suppose that only the true positive (24) and true negative (43) diagnoses of heart 
disease are reported. Without incorporating any additional information about the 
association between the cell counts, the resulting recovered contingency table based on the 
posterior means obtained through our methodology is presented in Table 17.  
Table 17: Recovered contingency table with uninformative prior 
  Disease No disease 
Test positive 24 13 
Test negative 7 43 
 
Considering that the model is based on a single observation and due to the prior being 
fairly non-informative, the performance of the model is not remarkable. The estimated false 
negatives were 7 (compared to the true value 10), and the estimated false positives were 13 
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(compared to the true value 4). While the estimated sensitivity of 0.77 is relatively close to 
the actual sensitivity of the test, 0.71, it is apparent that the estimated specificity of 0.77 is 
significantly lower than the true value, 0.91.  
Incorporating more information into the model through the priors leads to a 
significantly better performance. Figure 21 and Figure 22 below show the absolute 
deviation of the recovered cell counts 𝐵 and 𝐶 from their true values as we vary 𝑛1 and 𝑛2 
through the parameters 𝜆1 and 𝜆2. We let 𝑛1 vary anywhere from 𝐴 to 2𝐴 (that is from 24 
to 48). Similarly, we let 𝑛2 vary anywhere from 𝐷 to 2𝐷 (that is from 43 to 86). The true 
values for 𝑛1 and 𝑛2 are 34 and 47 respectively. 
Unsurprisingly, Figure 21 shows that the deviation of the estimate of 𝐵 from the 
original table increases as we increase 𝜆2 which governs the distribution on 𝑛2 (𝑛2 = 𝐵 +
𝐷). For any prior of 𝜆2 between 43 and 45, the posterior of 𝐵 (𝑛2) stayed within 3 deviations 
from the original cell count of 𝐵, 4 (original count 𝑛2,47). As 𝜆2 increased, the error 
increased. The estimator of 𝐵 was not affected by the prior on 𝜆1 which governs the 
distribution of 𝑛1.  
The effect of the priors on the posterior of 𝐶 showed an interesting pattern that can 
be observed in Figure 22. The two priors, 𝜆1 and 𝜆2 both influence 𝐶, and the posterior 
estimate of 𝐶 does not remain the same as we vary the prior on 𝜆2. The posterior of 𝐶 
generated by the model was within 1 deviation from the original value of 10 12.5% of the 
scenarios, and within 3 deviations from the original value about 37.49% of the time.  
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Figure 21. Deviation of B 
 
 
Figure 22. Deviation of C 
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APPENDIX A. SUPPLEMENTAL MATERIAL FOR CHAPTER 2 
A.1 Full search strategy for PubMed 
 Detailed search terms and strategy for title/abstract: (melanom* or melanocyt*) 
AND (BRAF or BRAF* or *RAF or MEK1 or MEK2 or MEK* or MAPK or ERK1 or 
ERK2 or ERK* or R05185426 or RG7204 or PLX 4032 or vemurafenib or zelboraf or 
dabrafenib or tanfilar or GSK 2118436 or GSK2118436 or GSK-2118436 or JTP 74057 or 
trametinib or mekinist or JTP74057 or JTP-74057 or GSK1120212 or GSK1120212 or 
GSK-1120212 or cobimetinib or cotellic or GDC-0973 or XL518 or pd-1 or pd-l1 or pd-l2 
or programmed cell death receptor or  programmed cell death 1 receptor or programmed 
cell death 2 receptor or CD279 or CLTA-4 or Cytotoxic T-Lymphocyte-Associated 
Antigen 4 or Cytotoxic T Lymphocyte Associated Antigen 4 or Cytotoxic T-Lymphocyte 
Antigen 4 or Cytotoxic T Lymphocyte Antigen 4 or CD152 or CD28 OR ipilimumab or 
MDX-CTLA-4 or Yervoy or MDX 010 or MDX010 or MDX-010 or tremelimumab or 
ticilimumab or CP 675 or CP675 or CP-675 or CP-675,206 or CP-675206 or CP675206 or 
CP 675206 or pidilizumab or nivolumab or opdivo or bms-936558 or ono-4538 or ono4538 
or mdx-1106 or pembrolizumab or lambrolizumab or keytruda or mk-3475) AND 
(random* or randomised or randomized or prospective). 
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A.2 Cochrane risk of bias tool 
 
Figure 23. Risk of bias analysis 
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A.3 Funnel plot of publication bias 
 
Figure 24. Funnel plot of all included studies (Overall survival outcome) 
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APPENDIX B. SUPPLEMENTAL MATERIAL FOR CHAPTER 3  
Table 18: All reported adverse events for enzalutamide vs. abiraterone in the pre- 
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Table 18 (Continued) 
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Table 18 (Continued) 
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Table 18 (Continued) 

























































Table 19: Sensitivity analysis meta-estimates for enzalutamide vs. abiraterone in the 















































Ratio < 1a 
0.60 
(0.58) 







































Ratio < 1a 
0.62 
(0.59) 
0.91 (0.85) 0.99 (0.98) 
1.00  
(1.00)b 
aPosterior probability (predictive probability); bodds ratio for response. 
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*Estimated parameters (not reported) 
NR, not reached  









































APPENDIX C. SUPPLEMENTAL MATERIAL FOR CHAPTER 4  
C.1 Heterogeneity 
 Table 21: Posterior median (95% CrI) costs (2018 USD), QALYs and ICERs 
for comparison of platinum doublet chemotherapy versus pembrolizumab as first-
line therapy for advanced NSCLC, under high level of study-to-study heterogeneity 
 Chemotherapy Pembrolizumab 



























































        
C.2 High dependency scenario  
In the third scenario, we incorporated a moderate dependency between each 
simulated patient’s outcomes in the pembrolizumab and chemotherapy arms and between 
their associated OS and progression times by introducing a correlation of 0.9 between the 
arms and a correlation of 0.9 between progression and OS times via a Gaussian copula. In 
the chemotherapy arm, posterior mean QALYs gained remained 1.06 as in the moderate 
dependency scenario. The mean cost in the chemotherapy arm remained almost unchanged 
in both the UK and US setting. Mean cost in the pembrolizumab arm increased from 
 132 
$121,000 to $123,000 in the UK setting, and from $160,000 to $164,000 in the US setting. 
In the absence of EoL adjustment, mean QALYs gained by patients on pembrolizumab 
decreased from 1.8 to 1.78, leading to ICER per QALY gained of $121,000 for the UK and 
$116,000 for the US. With EoL adjustment, ICERs per QALY gained for the UK and US 
setting were $62,000 and $60,000 respectively. See Table 22Table 22. The probability that 
pembrolizumab was cost-effective was 0.1% with respect to the UK (USD 42,048) 
threshold and 98.6% with respect to the US (USD 100,000) threshold in the presence of 
EoL adjustment. The probabilities were <1% and 9.3% with respect to the UK and US 
thresholds respectively in the absence of EoL adjustment. The results from this strong 
dependence scenario were similar to the moderate dependence scenario.  
Table 22: Posterior mean (95% CrI) costs (2018 USD), QALYs and ICERs for 
comparison of platinum doublet chemotherapy versus pembrolizumab as first-line therapy 
for advanced NSCLC, under strong dependency between patients’ hypothetical outcomes 
 Chemotherapy Pembrolizumab 
































































       
 133 
C.3 Analysis incorporating discounting 
We considered a discounting factor to adjust the costs and utilities for the 
pembrolizumab and chemotherapy arms to present values. We chose a discounting factor 
corresponding to 3% on an annual basis. Accumulated costs and utilities were multiplied 
by 1/(1+0.03)^n  , where n is the corresponding year in which the cost or utility occurred. 
The results were qualitatively unchanged with slightly higher ICER values and lower 
probabilities of pembrolizumab being cost effective. The results can be found in Table 23. 
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Table 23: Posterior mean (95% CrI) costs (2018 USD), QALYs and ICERs for 
comparison of platinum doublet chemotherapy versus pembrolizumab as first-line 
therapy for advanced NSCLC 
 Chemotherapy Pembrolizumab 






















































































































C.4 Analysis based on parametric survival model (Weibull distribution) 
We considered a parametric survival model using the Weibull distribution. We used 
the fitted parametric survival curves, to independently generate 10,000,000 progression 
and OS times and construct patient trajectories for the pembrolizumab and chemotherapy 
arms. The results are summarized in Table 24 below.  
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Table 24: Mean (95% CI) costs (2018 USD), QALYs and ICERs for comparison of 
platinum doublet chemotherapy versus pembrolizumab as first-line therapy for 
advanced NSCLC for Weibull survival model 
 Chemotherapy Pembrolizumab 
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